var title_f5_50_5920="Paraspinal ganglioneuroma CT";
var content_f5_50_5920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraspinal ganglioneuroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large mixed attenuation right paraspinal mass extends anteromedially and displaces and narrows the trachea to the left. The tumor originates most likely from the sympathetic chain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5920=[""].join("\n");
var outline_f5_50_5920=null;
var title_f5_50_5921="Metastatic ependymoma MRI";
var content_f5_50_5921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MR image of a spinal cord ependymoma (upper arrow) discovered to be metastatic to multiple sites within the neuraxis (lower arrows) at diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Kieran, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5921=[""].join("\n");
var outline_f5_50_5921=null;
var title_f5_50_5922="Patient information: Thyroiditis after pregnancy (The Basics)";
var content_f5_50_5922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85801\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"         Thyroid and parathyroid glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/9/22674\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Thyroiditis after pregnancy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6252011\">",
"      <span class=\"h1\">",
"       What is thyroiditis after pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Thyroiditis is a condition that happens when a gland in the neck called the thyroid gets inflamed (",
"      <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"       figure 1",
"      </a>",
"      ). This gland makes thyroid hormone, which controls how the body uses and stores energy.",
"     </p>",
"     <p>",
"      The thyroid gland sometimes makes too much or too little thyroid hormone. Hyperthyroidism is the medical term for when this gland makes too much thyroid hormone. Hypothyroidism is the medical term for when this gland makes too little thyroid hormone.",
"     </p>",
"     <p>",
"      Thyroiditis after pregnancy can cause hyperthyroidism, hypothyroidism, or both (1 after the other). This condition happens within a year of being pregnant. That means it can happen after a woman has a baby, miscarriage (when a pregnancy ends on its own), or abortion (when a woman chooses to end a pregnancy).",
"     </p>",
"     <p>",
"      The medical term for thyroiditis after pregnancy is &ldquo;postpartum thyroiditis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6252043\">",
"      <span class=\"h1\">",
"       What are the symptoms of thyroiditis after pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Thyroiditis after pregnancy can cause symptoms of hyperthyroidism or hypothyroidism. Sometimes people have symptoms of hyperthyroidism and then symptoms of hypothyroidism.",
"     </p>",
"     <p>",
"      Common symptoms of hyperthyroidism include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling tired or weak",
"       </li>",
"       <li>",
"        Losing weight, even when you eat normally",
"       </li>",
"       <li>",
"        Having a fast or uneven heartbeat",
"       </li>",
"       <li>",
"        Sweating a lot and having trouble dealing with hot weather",
"       </li>",
"       <li>",
"        Feeling worried",
"       </li>",
"       <li>",
"        Trembling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Common symptoms of hypothyroidism include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having no energy",
"       </li>",
"       <li>",
"        Feeling cold",
"       </li>",
"       <li>",
"        Trouble having bowel movements (constipation)",
"       </li>",
"       <li>",
"        Not making enough breast milk, if you are breastfeeding",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6252058\">",
"      <span class=\"h1\">",
"       Is there a test for thyroiditis after pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check if you have this condition, your doctor or nurse will ask about your symptoms, do an exam, and order blood tests.",
"     </p>",
"     <p>",
"      Sometimes doctors order other tests, such as an ultrasound of the thyroid gland. An ultrasound uses sound waves to create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6252073\">",
"      <span class=\"h1\">",
"       How is thyroiditis after pregnancy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In many cases, women don&rsquo;t need any treatment. The condition usually gets better on its own, and the thyroid gland works normally again. This usually takes 6 months to 1 year.",
"     </p>",
"     <p>",
"      Until you get better, your doctor will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do blood tests on a regular basis to check your thyroid hormone levels. If your condition worsens, you will need treatment.",
"       </li>",
"       <li>",
"        Treat your symptoms. Symptoms from hyperthyroidism are treated with medicines called &ldquo;beta blockers.&rdquo; Symptoms from hypothyroidism are treated with thyroid hormone pills.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Although uncommon, thyroiditis after pregnancy sometimes causes long-lasting hypothyroidism. If this happens, you will need life-long treatment with thyroid hormone pills.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6252088\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with thyroiditis after pregnancy are likely to get this condition again after future pregnancies. If you get pregnant again, let your doctor or nurse know so that he or she can monitor your thyroid hormone levels.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6252103\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/50/5922?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85801 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5922=[""].join("\n");
var outline_f5_50_5922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252011\">",
"      What is thyroiditis after pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252043\">",
"      What are the symptoms of thyroiditis after pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252058\">",
"      Is there a test for thyroiditis after pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252073\">",
"      How is thyroiditis after pregnancy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252088\">",
"      What if I want to get pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6252103\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"      Thyroid and parathyroid glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5923="Nail changes in reactive arthritis II";
var content_f5_50_5923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F83796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F83796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail changes in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Separation of the distal portion of the nails (onycholysis), accumulation of subungual keratotic debris, and periungual scale and erythema can occur in both reactive arthritis and psoriasis. &nbsp;Arthritis is present in addition to the dystrophic nail changes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5923=[""].join("\n");
var outline_f5_50_5923=null;
var title_f5_50_5924="Moxifloxacin (ophthalmic): Pediatric drug information";
var content_f5_50_5924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moxifloxacin (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=see_link\">",
"    see \"Moxifloxacin (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/45/9940?source=see_link\">",
"    see \"Moxifloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9347894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Moxeza&trade;;",
"     </li>",
"     <li>",
"      Vigamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9347895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vigamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F11164141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F11164149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=see_link\">",
"      see \"Moxifloxacin (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;4 months, Children, and Adults: Moxeza&trade;: Instill 1 drop into affected eye(s) 2 times daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;1 year and Adults: Vigamox&reg;: Instill 1 drop into affected eye(s) 3 times daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9348142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moxeza&trade;: 0.5% (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vigamox&reg;: 0.5% (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9347897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12923602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye, finger, or other surfaces. Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11164147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11164143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial conjunctivitis caused by susceptible organisms (Moxeza&trade;: FDA approved in ages &ge;4 months and adults; Vigamox&reg;: FDA approved in ages &ge;1 year and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9347832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vigamox [U.S., Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9347979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Ocular: Conjunctivitis, dry eye, ocular discomfort, ocular hyperemia, ocular irritation, ocular pain, ocular pruritus, subconjunctival hemorrhage, tearing, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11164144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to moxifloxacin, other quinolone antibiotics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F12923600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in fungal or bacterial superinfection. Contact lenses should not be worn during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11164145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy, including moxifloxacin. The spectrum of these reactions can vary widely. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"     <b>",
"      Not for injection into the eye.",
"     </b>",
"     Eye drops should not be introduced directly into the anterior chamber of the eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9347982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9347967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies moxifloxacin ophthalmic as pregnancy category C. Information related to moxifloxacin in pregnancy is limited. Refer to the Moxifloxacin (Systemic) monograph for available information. Quinolone exposure during human pregnancy has been reported with other agents (see Ciprofloxacin [Systemic], Ofloxacin [Systemic], and Norfloxacin [Systemic] monographs).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13896505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11164148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moxifloxacin is an inhibitor of DNA gyrase and topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12923601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Minimal systemic absorption; resulting serum concentration was 0.02% of that achieved with oral formulation",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F11164150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/45/9940?source=see_link\">",
"      see \"Moxifloxacin (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Wash hands before instilling solution. Sit or lie down to instill. Do not touch tip of applicator or let tip of applicator touch eye. Do not wear contact lenses during therapy. Temporary stinging, blurred vision, or dry eyes may occur. Report persistent pain, burning, excessive tearing, decreased visual acuity, swelling, itching, or worsening of condition. If signs of allergic reaction (eg, itching, rash, respiratory difficulty, facial edema, difficulty swallowing) occur, discontinue use immediately and contact prescriber.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F12923603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evidence of damage to weight-bearing joints in pediatric populations with ophthalmic administration has not been shown.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Silver LH, Woodside AM, and Montgomery DB, \"Clinical Safety of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX) in Pediatric and Nonpediatric Patients With Bacterial Conjunctivitis,\"",
"      <i>",
"       Surv Ophthalmol",
"      </i>",
"      , 2005, 50(Suppl 1):55-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5924/abstract-text/16257311/pubmed\" id=\"16257311\" target=\"_blank\">",
"        16257311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16756 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5924=[""].join("\n");
var outline_f5_50_5924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164141\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164149\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347897\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923602\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164147\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164143\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347832\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347979\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164144\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923600\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164145\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299728\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347982\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347967\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775710\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13896505\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164148\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923601\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11164150\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923603\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=related_link\">",
"      Moxifloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/45/9940?source=related_link\">",
"      Moxifloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/29/21976?source=related_link\">",
"      Moxifloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/51/2870?source=related_link\">",
"      Moxifloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5925="Prasugrel: Patient drug information";
var content_f5_50_5925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prasugrel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     see \"Prasugrel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7901908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effient&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14464693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Effient&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad bleeding. Stop this drug at least 7 days before heart surgery. If you are 75 years or older, talk with your doctor before using this drug. Follow how to take exactly. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart treatment to protect the arteries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prasugrel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems or history of stroke.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pinpoint red spots on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12218 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.248.109.99-8AB70CBFC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5925=[""].join("\n");
var outline_f5_50_5925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901908\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464693\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011313\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011315\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011314\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011319\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011320\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011322\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011317\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011318\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011323\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011324\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=related_link\">",
"      Prasugrel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5926="Insulin aspart protamine and insulin aspart: Pediatric drug information";
var content_f5_50_5926=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin aspart protamine and insulin aspart: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3655?source=see_link\">",
"    see \"Insulin aspart protamine and insulin aspart: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8229?source=see_link\">",
"    see \"Insulin aspart protamine and insulin aspart: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2169301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoLOG&reg; Mix 70/30;",
"     </li>",
"     <li>",
"      NovoLOG&reg; Mix 70/30 FlexPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4782805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NovoMix&reg; 30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2984516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3655?source=see_link\">",
"      see \"Insulin aspart protamine and insulin aspart: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin aspart protamine is an intermediate-acting insulin and insulin aspart is a rapid-acting insulin administered by SubQ injection. Insulin aspart protamine and insulin aspart combination products are approximately equipotent to insulin NPH and insulin regular combination products with a similar duration of activity, but with a more rapid onset. With combination insulin products, the proportion of rapid-acting to long-acting insulin is fixed; basal vs prandial dose adjustments cannot be made. Fixed ratio insulins (such as insulin aspart protamine and insulin aspart combination) are typically  administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     . Insulin aspart protamine and insulin aspart combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Insulin aspart protamine and insulin aspart combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLOG&reg; Mix 70/30: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLOG&reg; Mix 70/30 FlexPen&reg;: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2343844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2984517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: SubQ: Gently roll vial or pen in the palms of the hands to resuspend before use; administer into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. Cold injections should be avoided. Administer within 15 minutes before a meal (type 1 diabetes) or 15 minutes before or after a meal (type 2 diabetes) (eg, before breakfast and supper). Do not mix or dilute with other insulins.",
"     <b>",
"      Not for I.V. administration",
"     </b>",
"     or use in an insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2136543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine, insulin glulisine, insulin lispro, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened container in refrigerator; do not freeze; protect from light. If refrigeration is not possible, vial (in use) may be stored at room temperature for up to 28 days. The pen (in use) should not be refrigerated; store below 30&deg;C (86&deg;F) away from direct heat or light; discard after 14 days. Do not mix or dilute with other insulins.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2984508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NovoLOG&reg; Mix 70/30 may be confused with HumaLOG&reg; Mix 75/25&trade;, HumuLIN&reg; 70/30, NovoLIN&reg; 70/30, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2176663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Palpitation, pallor, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (including edema, itching, pain or warmth, stinging), lipoatrophy, lipodystrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, antibodies to insulin (no change in efficacy), diaphoresis, local allergy, systemic allergic symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity insulin aspart, insulin aspart protamine, or to any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2984511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating. Not for I.V. infusion or use in insulin infusion pumps.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8102566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2136515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2137901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Biphasic insulin aspart (insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]) was found to be comparable to biphasic human insulin (Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]) in a pilot study of women with gestational diabetes mellitus. All pregnancies have a background risk of adverse outcome; this risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. Most available information for use of insulin aspart in pregnancy is from studies using the rapid action solution.  Refer to Insulin Aspart monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Insulin aspart protamine and insulin aspart is a combination insulin product with intermediate-acting characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 18-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: &le;9%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Half-life: 8-9 hours (mean)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak serum concentration: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8229?source=see_link\">",
"      see \"Insulin aspart protamine and insulin aspart: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12539 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5926=[""].join("\n");
var outline_f5_50_5926=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2169301\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4782805\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984507\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984516\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104231\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2343844\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136543\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984513\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984508\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136512\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2176663\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984519\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984511\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102566\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221026\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984521\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136515\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984523\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984524\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984514\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984522\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984515\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984525\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455318\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3655?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8229?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5927="Remifentanil: Drug information";
var content_f5_50_5927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Remifentanil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/41/38547?source=see_link\">",
"    see \"Remifentanil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/56/31622?source=see_link\">",
"    see \"Remifentanil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ultiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ultiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Anilidopiperidine Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anesthesia: I.V. continuous infusion:",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be based on ideal body weight (IBW) in obese patients (&gt;30% over IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Induction of anesthesia:",
"     </b>",
"     0.5-1 mcg/kg/minute; if endotracheal intubation is to occur in &lt;8 minutes, an initial dose of 1 mcg/kg may be given over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Coronary bypass surgery:",
"     </i>",
"     1 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of anesthesia:",
"     </b>",
"     Supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments of 25% to 100% or downward in decrements of 25% to 50%. May titrate every 2-5 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With nitrous oxide (66%):",
"     </i>",
"     0.4 mcg/kg/minute (range: 0.1-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With isoflurane:",
"     </i>",
"     0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With propofol:",
"     </i>",
"     0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Coronary bypass surgery:",
"     </i>",
"     1 mcg/kg/minute (range: 0.125-4 mcg/kg/minute); supplemental dose: 0.5-1 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Continuation as an analgesic in immediate postoperative period:",
"     </b>",
"     0.1 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute). Infusion rate may be adjusted every 5 minutes in increments of 0.025 mcg/kg/minute. Bolus doses are not recommended. Infusion rates &gt;0.2 mcg/kg/minute are associated with respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Coronary bypass surgery, continuation as an analgesic into the ICU:",
"     </i>",
"     1 mcg/kg/minute (range: 0.05-1 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic component of monitored anesthesia care:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Supplemental oxygen is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Single I.V. dose given 90 seconds prior to local anesthetic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Remifentanil alone: 1 mcg/kg over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With midazolam: 0.5 mcg/kg over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion beginning 5 minutes prior to local anesthetic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Remifentanil alone: 0.1 mcg/kg minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With midazolam: 0.05 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion given after local anesthetic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Remifentanil alone: 0.05 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With midazolam: 0.025 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Following local or anesthetic block, infusion rate should be decreased to 0.05 mcg/kg/minute; rate adjustments of 0.025 mcg/kg/minute may be done at 5-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Critically-ill patients (unlabeled dose):",
"     </b>",
"     Loading dose: 1.5 mcg/kg; followed by 0.008-0.25 mcg/kg/minute (",
"     <b>",
"      or",
"     </b>",
"     0.5-15 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/56/31622?source=see_link\">",
"      see \"Remifentanil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be based on ideal body weight (IBW) in obese patients (&gt;30% over IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of anesthesia with nitrous oxide (70%):",
"     </b>",
"     Children Birth to 2 months: Continuous I.V. infusion: 0.4 mcg/kg/minute (range: 0.4-1 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered, smaller bolus dose may be required with potent inhalation agents, potent neuraxial anesthesia, significant comorbidities, significant fluid shifts, or without atropine pretreatment. Clearance in neonates is highly variable; dose should be carefully titrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of anesthesia with halothane, sevoflurane, or isoflurane:",
"     </b>",
"     Continuous I.V. infusion: Children 1-12 years: 0.25 mcg/kg/minute (range: 0.05-1.3 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments up to 50% or titrated downward in decrements of 25% to 50%. May titrate every 2-5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly patients have an increased sensitivity to effect of remifentanil; doses should be decreased by 50% and titrated. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultiva&reg;: 1 mg, 2 mg, 5 mg [contains glycine 15 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F217553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An infusion device should be used to administer continuous infusions. During the maintenance of general anesthesia, I.V. boluses may be administered over 30-60 seconds. Injections should be given into I.V. tubing close to the venous cannula; tubing should be cleared after treatment to prevent residual effects when other fluids are administered through the same I.V. line.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with blood products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alfentanil, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, furosemide, ganciclovir, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, minocycline, morphine, nalbuphine, nitroglycerin, norepinephrine, ofloxacin, ondansetron, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, sufentanil, theophylline, thiopental, ticarcillin/clavulanate potassium, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, chlorpromazine, diazepam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic for use during the induction and maintenance of general anesthesia; for continued analgesia into the immediate postoperative period; analgesic component of monitored anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F217547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of pain in mechanically-ventilated patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Remifentanil may be confused with alfentanil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency of adverse events may vary based on surgical procedures and rate of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (2% to 19%), bradycardia (1% to 7%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&lt;2% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&lt;2% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&lt;36% to 44%), vomiting (&lt;16% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle rigidity (&lt;1% to 11%; includes chest wall rigidity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (1% to 2%; dose dependent), tachycardia (&le;1%; dose dependent), flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (&lt;5%), dizziness (&lt;5%), postoperative pain (&lt;2%), chills (1%), agitation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression (&lt;7%), apnea (&lt;3%), hypoxia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (6%), shivering (&lt;5%), warm sensation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal discomfort, amnesia, anaphylaxis,  anxiety, arrhythmias, awareness under anesthesia without pain, bronchitis, bronchospasm, chest pain, confusion, constipation, cough, CPK increased, diarrhea, disorientation, dysphagia, dysphoria, dyspnea, dysuria, ECG changes, electrolyte disorders, erythema, gastroesophageal reflux, hallucinations, heart block, heartburn, hiccups, hyperglycemia, ileus, incontinence, involuntary movement, laryngospasm, leukocytosis, liver dysfunction, lymphopenia, nasal congestion, nightmares, nystagmus, oliguria, paresthesia,  pharyngitis, pleural effusion, prolonged emergence from anesthesia, pulmonary edema, rales, rapid awakening from anesthesia, rash, rhinorrhea, rhonchi, seizure, sleep disturbance, stridor, syncope, temperature regulation impaired, thrombocytopenia, tremors, twitching, urine retention, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for intrathecal or epidural administration, due to the presence of glycine in the formulation; hypersensitivity to remifentanil, fentanyl, or fentanyl analogs, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intraoperative awareness: In patients &lt;55 years of age, intraoperative awareness has been reported when used with propofol rates of &le;75 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid agonist toxicities: Shares the toxic potentials of opioid agonists, and precautions of opioid agonist therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: Use with caution when administering to patients with bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Interruption of an infusion will result in offset of effects within 5-10 minutes; the discontinuation of infusion should be preceded by the establishment of adequate postoperative analgesia orders, especially for patients in whom postoperative pain is anticipated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; General anesthesia use: Not recommended as the sole agent for induction of anesthesia, because the loss of consciousness cannot be assured.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid infusion: Rapid I.V. infusion (single dose &gt;1 mcg/kg over 30-60 seconds and infusion rates &gt;0.1 mcg/kg/minute) should only be used during maintenance of general anesthesia; may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required. Chest wall rigidity may resolve by decreasing the infusion rate or temporarily stopping the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained individuals: Due to the high incidence of respiratory depression, apnea, hypotension, tachycardia and muscle rigidity, remifentanil should only be administered by individuals specifically trained in the use of anesthetic agents. Should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Inadequate clearing of I.V. tubing following remifentanil administration could result in chest wall rigidity, respiratory depression, and apnea when another fluid is administered through the same line.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Remifentanil has been shown to cross the placenta; fetal and maternal concentrations may be similar. Maternal apnea, as well as neonatal respiratory depression and sedation, may occur (Montgomery, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14455863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Remifentanil has a limited duration of action; use may be appropriate for breast-feeding women undergoing short procedures (Montgomery, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ultiva Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $55.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $110.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $234.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Restinil (UY);",
"     </li>",
"     <li>",
"      Ultiva (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MX, NI, NL, NO, OM, PA, PE, PL, PT, QA, SA, SE, SG, SR, SV, SY, TT, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific mu-opioid receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 1-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 100 mL/kg; increased in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~70% (primarily alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid via blood and tissue esterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (dose dependent): Terminal: 10-20 minutes; effective: 3-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkle H, Dunbar S, and Van Aken H, &ldquo;Remifentanil: A Novel, Short-Acting, &mu;-Opioid,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 83(3):646-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/8780298/pubmed\" id=\"8780298\" target=\"_blank\">",
"        8780298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glass PS, &ldquo;Remifentanil: A New Opioid,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1995, 7(7):558-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/8652166/pubmed\" id=\"8652166\" target=\"_blank\">",
"        8652166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogue CW, Bowdle TA, O'Leary C, et al, &ldquo;A Multicenter Evaluation of Total Intravenous Anesthesia With Remifentanil and Propofol for Elective Inpatient Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 83(2):279-285.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/8694306/pubmed\" id=\"8694306\" target=\"_blank\">",
"        8694306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kapila A, Glass PS, Jacobs JR, et al, &ldquo;Measured Context-Sensitive Half-Times of Remifentanil and Alfentanil,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 83(5):968-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/7486182/pubmed\" id=\"7486182\" target=\"_blank\">",
"        7486182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montgomery A and Hale TW, et al &ldquo;ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2006, 1(4):271-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/17661608/pubmed\" id=\"17661608\" target=\"_blank\">",
"        17661608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosow C, &ldquo;Remifentanil: A Unique Opioid Analgesic,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1993, 79(5):875-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/7902031/pubmed\" id=\"7902031\" target=\"_blank\">",
"        7902031",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warner DS, Hindman BJ, Todd MM, et al, &ldquo;Intracranial Pressure and Hemodynamic Effects of Remifentanil Versus Alfentanil in Patients Undergoing Supratentorial Craniotomy,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 83(2):348-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/8694317/pubmed\" id=\"8694317\" target=\"_blank\">",
"        8694317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westmoreland CL, Hoke JF, Sebel PS, et al, &ldquo;Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient Surgery,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1993, 79(5):893-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/50/5927/abstract-text/7902033/pubmed\" id=\"7902033\" target=\"_blank\">",
"        7902033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9854 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-790B5E06CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5927=[""].join("\n");
var outline_f5_50_5927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217521\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217522\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217551\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217525\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217538\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217526\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217497\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217482\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217553\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217501\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217558\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217500\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217547\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217560\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217549\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217504\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217486\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299990\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217491\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217507\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217528\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455863\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323781\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217494\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217508\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217485\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217503\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9854|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/41/38547?source=related_link\">",
"      Remifentanil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/56/31622?source=related_link\">",
"      Remifentanil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5928="Gastrointestinal manifestations of systemic lupus erythematosus";
var content_f5_50_5928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Elena M Massarotti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5928/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5928/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/50/5928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) manifestations occur in approximately 25 to 40 percent of patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Many of these symptoms are nonspecific, and often reflect either lupus of the GI tract or the effects of medications.",
"   </p>",
"   <p>",
"    The gastrointestinal manifestations of SLE in adults will be reviewed here. Overviews of the clinical manifestations and treatment of SLE in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DYSPHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The esophagus is involved in 1.5 to 25 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Dysphagia is the most frequent complaint and is usually due to esophageal hypomotility. One study, for example, evaluated fourteen patients with SLE and dysphagia: seven had an esophageal motility problem, which was associated with aperistalsis in three [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/5\">",
"     5",
"    </a>",
"    ]. The swallowing difficulty tends to be episodic and greatest during periods of stress. Esophageal dysfunction is frequently associated with the Raynaud phenomenon and the presence of anti-ribonucleoprotein antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which lupus leads to esophageal dysmotility is not known. It may be caused by an inflammatory reaction in the esophageal muscles, or by ischemic or vasculitic changes to Auerbach's plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to esophageal hypomotility, dysphagia in patients with SLE may also be caused by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal stricture",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (GERD), which can result in esophagitis, esophageal spasm, and stricture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Esophageal candidiasis can occur, especially in patients treated with antibiotics, glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunosuppressive agents.",
"     </li>",
"     <li>",
"      Ulcers of the esophagus have rarely been noted; why they occur is not known.",
"     </li>",
"     <li>",
"      Medication-induced inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"       \"Medication-induced esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the oropharynx either directly or by radiography rarely reveals any abnormality. Radiographic and manometric studies of the esophagus may show abnormal peristalsis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/5\">",
"     5",
"    </a>",
"    ], while endoscopy and radiography of the esophagus often will demonstrate other treatable causes of dysphagia (eg, stricture, esophagitis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of esophageal symptoms depends upon the specific etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypomotility can be treated with cisapride (10 mg four times per day). However, cisapride has been associated with a number of drug interactions and fatal cardiac arrhythmias prompting the manufacturer to severely restrict its availability in the United States. As of August 2000, prescriptions for the drug can only be filled directly through the manufacturer after providing documentation as to need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient.",
"     </li>",
"     <li>",
"      Esophageal stricture is treated by endoscopic dilatation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eating frequent small meals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"       \"Complications of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms due to GERD may be treated by reflux precautions (eg, elevating the head of the bed, avoiding postprandial recumbency), and, depending upon the severity, the administration of antacids, H2 antagonists, or a proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"       \"Medical management of gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Esophageal candidiasis is treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain, accompanied by nausea and vomiting, occurs in up to 30 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The differential diagnosis does not differ significantly from that in patients without lupus. However, special consideration should be given to disorders that may be associated with lupus such as infection, peritonitis, peptic ulcer disease, mesenteric vasculitis with intestinal infarction, pancreatitis, and inflammatory bowel disease. In immunosuppressed patients, Infection with cytomegalovirus may cause abdominal pain and gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific cause of abdominal pain is usually established through the use of CT scan, endoscopy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies, ultrasound, angiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paracentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An often overlooked cause of abdominal pain in SLE is peritonitis. Although clinical peritonitis is rarely suspected, autopsy studies suggest that 60 to 70 percent of patients with SLE have had an episode of peritonitis at some time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1\">",
"     1",
"    </a>",
"    ]. If peritonitis is suspected (due, for example, to rebound tenderness on physical examination) and CT scan shows intraperitoneal fluid, a paracentesis is warranted to exclude infection. In our and others experience, abdominal pain of uncertain cause occasionally responds to steroids, suggesting an inflammatory mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, if a transudate is found on paracentesis, a trial of glucocorticoids (60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day or its equivalent) may be warranted if symptoms are moderate to severe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascites is uncommon in SLE. When detected, peritonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforation should be excluded by paracentesis. Other possible causes of ascites related to lupus include congestive heart failure and hypoalbuminemia, which may be due to the nephrotic syndrome or protein-losing enteropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PEPTIC ULCER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspepsia has been noted in 11 to 50 percent of patients with SLE, while peptic ulcers (usually gastric) are present in 4 to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/6\">",
"     6",
"    </a>",
"    ]. These complications are more common in patients treated with nonsteroidal antiinflammatory drugs (NSAIDs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .) Glucocorticoids also increase the incidence of dyspepsia and may produce a slight increase in peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, it has been suggested that SLE itself predisposes to ulcer formation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/7\">",
"     7",
"    </a>",
"    ]. How this might occur is not known. Bleeding from peptic ulcer disease in SLE is uncommon and perforation is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of dyspepsia or peptic ulcer disease are usually evaluated by endoscopy. These complications may respond to medication withdrawal. If therapy must be continued or symptoms persist, the patient can be treated in the same fashion employed for patients with these findings in the absence of SLE. Cessation of cigarette smoking and excess alcohol consumption should always be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of Helicobacter pylori infection in peptic ulcers in patients with lupus is not well defined. Testing for Helicobacter infection may be indicated in patients with peptic ulcers (particularly duodenal) or related symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic therapy also may be beneficial in certain settings such as patients with dyspepsia, a history of peptic ulcer disease, or combined therapy with an NSAID and high dose glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MESENTERIC VASCULITIS AND INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain secondary to mesenteric vasculitis is generally an insidious symptom that may be intermittent for months prior to the development of an acute abdomen with nausea, vomiting, diarrhea, GI bleeding, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,3,12\">",
"     1,3,12",
"    </a>",
"    ]. Risk factors for the development of mesenteric vasculitis include peripheral vasculitis and central nervous system lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with an acute presentation may also have mesenteric thrombosis and infarction, often in association with antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mesenteric vasculitis is a life-threatening disorder. In addition to the possible development of necrotic segments of bowel, patients may suffer septic complications and bowel perforation. Older studies found death due to perforation occurred in 1 to 2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Perforations typically occurred in patients with severe active lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its insidious and intermittent nature, the diagnosis of mesenteric vasculitis may be difficult to establish. During the early stages, plain radiographic studies may reveal nondiagnostic findings such as segmental bowel dilatation, air-fluid levels, \"thumbprinting\" or narrowing of the lumen, and pseudoobstruction.",
"   </p>",
"   <p>",
"    Abdominal CT scan may be more helpful. In one study of 15 women with SLE presenting with abdominal pain, a CT of the abdomen was performed within one to four days of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/18\">",
"     18",
"    </a>",
"    ]. CT features thought to be representative of mesenteric vasculitis included conspicuous prominence of mesenteric vessels with a palisading pattern or comb-like appearance supplying dilated bowel loops; other findings included ascites and small bowel thickening. The role of abdominal CT in this setting is unclear, and arteriography is usually needed for a definitive diagnosis (see below).",
"   </p>",
"   <p>",
"    Arteriography may reveal evidence of vasculitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia of the small intestine or colon. Vasculitis generally involves small arteries, which can lead to a negative arteriogram. The diagnosis in such patients may be made at surgery or, after the acute episode has resolved, by colonoscopy and biopsy.",
"   </p>",
"   <p>",
"    Patients with acute abdominal symptoms are kept NPO, blood cultures are obtained, and broad spectrum antibiotics are administered. Some authors have advocated treatment with 1 to 2 mg",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"      prednisolone",
"     </a>",
"     /kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. We and others have used the following regimen in patients suspected of suspected of mesenteric vasculitis without perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One to three courses of intravenous pulse steroids (1000 to 1500 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      over two hours per day)",
"      <strong>",
"       PLUS",
"      </strong>",
"      a bolus of pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (1000 mg IV) are administrated immediately to suppress the inflammatory response.",
"     </li>",
"     <li>",
"      After 7 to 10 days, if feasible, the patient is given another bolus of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      body surface area), usually in the morning with intravenous saline loading.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery to remove ischemic bowel is performed if the patient with acute disease has evidence of perforation or fails to respond promptly to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PANCREATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis occurs in as many as 2 to 8 percent of patients, usually in those with active SLE elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,21-23\">",
"     1,21-23",
"    </a>",
"    ]. The presentation does not differ from patients without SLE, and includes upper abdominal pain, nausea and vomiting, and an increase in serum amylase and lipase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    .) However, elevated levels of serum amylase have also been detected in patients with SLE in the absence of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, this laboratory finding must always be interpreted in light of the overall clinical exam.",
"   </p>",
"   <p>",
"    The differential diagnosis of abdominal pain and an elevated amylase should include mesenteric infarction, perforated peptic ulcer, ruptured ectopic pregnancy, some tumors, and renal failure (in which the serum amylase concentration does not exceed twice the upper limit of normal). Imaging studies (eg, CT scan or ultrasound) often help to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatitis due to lupus may result from vasculitis or thrombosis (often in association with antiphospholipid antibodies). Other contributing factors, as in patients without lupus, include hepatobiliary disease, alcoholism, infection, NSAIDs, metabolic disorders (eg, hyperlipidemia) and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and glucocorticoids, two immunosuppressants that have been implicated as causes of acute pancreatitis in patients who do not have SLE, are not a clear risk factor in patients with lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/23\">",
"     23",
"    </a>",
"    ]. Use of these agents in patients with SLE may be associated with a more favorable outcome (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In one series of 53 patients presenting with SLE and abdominal pain, 20 had a clinical diagnosis of acute pancreatitis. In four, no contributing factor other than lupus could be identified. No serious complications occurred in these patients, and recovery ensued despite continuing steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, pancreatitis generally responds to usual medical treatment including intravenous fluids, keeping the patient NPO, and cessation of drugs that might be responsible for the pancreatitis. However, others have noted a short-term mortality rate of 20 percent for patients with SLE who develop pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who do not rapidly respond and who have otherwise unexplained pancreatitis which may be due to lupus itself, systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses) may be given, particularly if there is clear evidence for active lupus elsewhere. In a number of patients, steroids have been continued without any apparent delay in clearing of the pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 77 cases of acute pancreatitis in patients with SLE concluded that use of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be associated with a reduced mortality from acute pancreatitis when compared to patients not receiving these drugs (20 percent versus with 61 percent mortality) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, unless the onset of pancreatitis is clearly temporally related to the initiation of azathioprine or glucocorticoids, and if these drugs are otherwise indicated to treat active SLE, it may be appropriate to initiate, or continue, their use in patients with SLE who have no other apparent cause for pancreatitis other than lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LIVER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatomegaly has been reported in up to 50 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/1,25-28\">",
"     1,25-28",
"    </a>",
"    ]. However, this figure generally refers to a palpable liver, and may not represent an enlarged liver. Jaundice is rare, and may reflect hemolysis rather than liver disease. Liver chemistries (LFTs, eg, AST, ALT, LDH, alkaline phosphatase) may be abnormal in patients with active lupus or in patients receiving NSAIDs.",
"   </p>",
"   <p>",
"    Studies of patients with SLE have demonstrated a number of liver abnormalities that are relatively common, and may even be severe and progressive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 206 patients, 124 had at least one abnormal liver chemistry and 43 met strict criteria for the existence of liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/25\">",
"       25",
"      </a>",
"      ]. In most cases, a specific viral or drug etiology could not be implicated. Liver biopsy in 33 patients with persistent liver chemistry abnormalities found a number of abnormalities, including: cirrhosis (in four patients, three of whom had a peculiar form of cholestasis); chronic active hepatitis; granulomatous hepatitis; cholestasis; centrilobular necrosis; chronic persistent hepatitis; primary biliary cirrhosis; steatosis; fatty liver; and drug toxicity. Of nine patients who had serial liver biopsies, four showed progression and three died.",
"     </li>",
"     <li>",
"      A retrospective study of the records of 192 patients with SLE identified 40 with hepatic involvement that was evaluated by a gastroenterologist [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/29\">",
"       29",
"      </a>",
"      ]. Disorders identified included the following: 3 patients with primary biliary cirrhosis, 4 with drug induced LFT abnormalities, 6 with autoimmune hepatitis, 8 with nonalcoholic fatty liver, 8 with viral hepatitis, and 11 with other hepatic diseases. The authors of this study concluded that patients with SLE commonly have LFT abnormalities, but end-stage liver disease with portal hypertension and cirrhosis is a rare manifestation.",
"     </li>",
"     <li>",
"      A study of liver samples from 52 patients with SLE (51 at autopsy and one liver biopsy) found hepatic congestion in 40, fatty liver in 38, arteritis in 11, cholestasis in 9, peliosis hepatitis in 6, chronic persistent hepatitis in 6, reactive hepatitis in 6, cholangiolitis in 4, nodular regenerative hyperplasia in 3, and hemangioma in 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/26\">",
"       26",
"      </a>",
"      ]. Fatty liver was associated with the glucocorticoid dosage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential causes of either liver enzyme abnormalities or overt liver disease include SLE itself (\"lupus hepatitis\"), NSAIDs, and coincidental disease. One study found a strong association between the presence of antibodies to ribosomal P protein and lupus hepatitis; the antibody was present in all six patients with hepatitis compared to only two to twenty without liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=see_link\">",
"     \"Antiribosomal P protein antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver chemistry abnormalities may resolve with cessation of NSAID use or the treatment of active SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lupoid hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term lupoid hepatitis was formerly used to describe autoimmune hepatitis because of clinical and serologic similarities to systemic lupus erythematosus. Autoimmune liver disease is relatively uncommon in patients with SLE. As an example, in a retrospective review of 377 adult patients with SLE, only five (1.3 percent) had histologically confirmed liver damage with autoimmune features [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune hepatitis may be associated with a number of autoimmune extrahepatic disorders similar to lupus. Autoantibodies may help to distinguish between autoimmune hepatitis and liver disease associated with lupus. Although antinuclear antibodies can be seen in both conditions, anti-smooth muscle and antimitochondrial antibodies are rare in lupus; thus, their presence suggests that the patient has autoimmune hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .) The absence of these antibodies and the presence of antiribosomal P protein antibodies suggest lupus hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROTEIN-LOSING ENTEROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-losing enteropathy in patients with SLE has been noted in a number of small series and case reports. The entity typically occurs in young women, and is characterized by the onset of profound edema and hypoalbuminemia in the absence of nephrotic range proteinuria. It may represent the first manifestation of SLE. Diarrhea is present in 50 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of protein losing enteropathy may be supported by scintigraphy, which demonstrates the presence of radio-labeled albumin in the GI tract following intravenous injection of Tc-99 labeled albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. A normal lymphocyte count, elevated serum cholesterol, and absence of lymphangiectasia on intestinal biopsy help distinguish this disorder from protein-losing enteropathies due to lymphatic obstruction. Patients typically respond well to treatment with glucocorticoids, although immunosuppressive drugs have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5928/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H742100\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal (GI) manifestations occur in approximately 25 to 40 percent of patients with systemic lupus erythematosus (SLE). Many of these symptoms are nonspecific, and often reflect either lupus of the GI tract or the effects of medications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysphagia is the most frequent gastrointestinal complaint in SLE and is usually due to esophageal hypomotility. Other causes include esophageal stricture, gastroesophageal reflux, esophageal candidiasis, esophageal ulcers, and medication&ndash;induced esophagitis. Radiographic and manometric studies of the esophagus may show abnormal peristalsis, while endoscopy and radiography of the esophagus can demonstrate other treatable causes of dysphagia. The treatment of esophageal symptoms depends upon the specific etiology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dysphagia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain, accompanied by nausea and vomiting, occurs in up to 30 percent of patients with SLE. The differential diagnosis does not differ significantly from that in patients without lupus, although attention should be given to disorders that may be associated with lupus such as infection, peritonitis, peptic ulcer disease, mesenteric vasculitis with intestinal infarction, pancreatitis, and inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Abdominal pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyspepsia has been noted in 11 to 50 percent of patients with SLE, while peptic ulcers (usually gastric) are present in 4 to 21 percent. These complications are more common in patients treated with nonsteroidal antiinflammatory drugs (NSAIDs), but SLE itself may also predispose to ulcer formation. Glucocorticoids also increase the incidence of dyspepsia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Peptic ulcer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mesenteric vasculitis is potentially life-threatening. The presentation may be insidious, with lower abdominal pain that is intermittent for months prior to the development of an acute abdomen with nausea, vomiting, diarrhea, GI bleeding, and fever. Patients with an acute presentation may also have mesenteric thrombosis and infarction, often in association with antiphospholipid antibodies. Radiographs and abdominal computerized tomographic (CT) scanning may show nonspecific but suggestive findings, but arteriography is usually required for diagnosis. Treatment includes antibiotics, high dose glucocorticoids, and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mesenteric vasculitis and infarction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pancreatitis occurs in less than 10 percent of patients, usually in those with active SLE elsewhere. The presentation does not differ from patients without SLE, and includes upper abdominal pain, nausea and vomiting, and an increase in serum amylase. Elevated levels of serum amylase have also been detected in patients with SLE in the absence of pancreatitis. The differential diagnosis of abdominal pain and an elevated amylase should include mesenteric infarction, perforated peptic ulcer, ruptured ectopic pregnancy, some tumors, and renal failure. Imaging studies (eg, CT scan or ultrasound) often help to confirm the diagnosis. Some patients require glucocorticoids in addition to usual medical treatment. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pancreatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential causes of either liver enzyme abnormalities or overt liver disease include SLE itself (\"lupus hepatitis\"), NSAIDs, and coincidental disease. Liver chemistry abnormalities may resolve with cessation of NSAID use or the treatment of active SLE. Liver abnormalities are common; hepatomegaly has been reported in up to 50 percent of patients with SLE. Jaundice is rare, and may reflect hemolysis rather than liver disease. Some liver disease in SLE may be severe and progressive. The term &ldquo;lupoid hepatitis&rdquo; refers to autoimmune hepatitis rather than liver involvement in SLE. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Liver disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Lupoid hepatitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein-losing enteropathy in patients with SLE has been noted in a number of small series and case reports. The entity typically occurs in young women, and is characterized by the onset of profound edema and hypoalbuminemia, and half of patients have diarrhea. It may represent the first manifestation of SLE. Patients typically respond well to glucocorticoids or immunosuppressives. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Protein-losing enteropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/1\">",
"      Hoffman BI, Katz WA. The gastrointestinal manifestations of systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 1980; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/2\">",
"      Jovaisas A, Kraag G. Acute gastrointestinal manifestations of systemic lupus erythematosus. Can J Surg 1987; 30:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/3\">",
"      Zizic TM, Classen JN, Stevens MB. Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 1982; 73:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/4\">",
"      Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999; 38:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/5\">",
"      Gutierrez F, Valenzuela JE, Ehresmann GR, et al. Esophageal dysfunction in patients with mixed connective tissue diseases and systemic lupus erythematosus. Dig Dis Sci 1982; 27:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/6\">",
"      Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol 1998; 25:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/7\">",
"      Ginzler EM, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheumatol 1998; 12:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/8\">",
"      Ramos-Casals M, Cuadrado MJ, Alba P, et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 2008; 87:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/9\">",
"      Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/10\">",
"      Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/11\">",
"      Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/12\">",
"      Shapeero LG, Myers A, Oberkircher PE, Miller WT. Acute reversible lupus vasculitis of the gastrointestinal tract. Radiology 1974; 112:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/13\">",
"      S&aacute;nchez-Guerrero J, Reyes E, Alarc&oacute;n-Segovia D. Primary antiphospholipid syndrome as a cause of intestinal infarction. J Rheumatol 1992; 19:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/14\">",
"      Nadorra RL, Nakazato Y, Landing BH. Pathologic features of gastrointestinal tract lesions in childhood-onset systemic lupus erythematosus: study of 26 patients, with review of the literature. Pediatr Pathol 1987; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/15\">",
"      Kaushik S, Federle MP, Schur PH, et al. Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients. Radiology 2001; 218:768.",
"     </a>",
"    </li>",
"    <li>",
"     Rothfield N. Systemic lupus erythematosus: Clinical and laboratory aspects. In: Arthritis and Allied Conditions, 9th, McCarty D (Ed), Lea and Febiger, Philadelphia 1979. p.691.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/17\">",
"      Zizic TM, Shulman LE, Stevens MB. Colonic perforations in systemic lupus erythematosus. Medicine (Baltimore) 1975; 54:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/18\">",
"      Ko SF, Lee TY, Cheng TT, et al. CT findings at lupus mesenteric vasculitis. Acta Radiol 1997; 38:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/19\">",
"      Lee CK, Ahn MS, Lee EY, et al. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis 2002; 61:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/20\">",
"      Hiraishi H, Konishi T, Ota S, et al. Massive gastrointestinal hemorrhage in systemic lupus erythematosus: successful treatment with corticosteroid pulse therapy. Am J Gastroenterol 1999; 94:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/21\">",
"      Reynolds JC, Inman RD, Kimberly RP, et al. Acute pancreatitis in systemic lupus erythematosus: report of twenty cases and a review of the literature. Medicine (Baltimore) 1982; 61:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/22\">",
"      Pascual-Ramos V, Duarte-Rojo A, Villa AR, et al. Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis. J Rheumatol 2004; 31:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/23\">",
"      Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum 2006; 35:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/24\">",
"      Sugiyama M, Wada N, Atomi Y, et al. Diagnosis of acute pancreatitis: value of endoscopic sonography. AJR Am J Roentgenol 1995; 165:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/25\">",
"      Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980; 69:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/26\">",
"      Matsumoto T, Yoshimine T, Shimouchi K, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol 1992; 23:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/27\">",
"      Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med 1984; 53:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/28\">",
"      van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med 1996; 48:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/29\">",
"      Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol 2008; 35:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/30\">",
"      Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/31\">",
"      Irving KS, Sen D, Tahir H, et al. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases. Rheumatology (Oxford) 2007; 46:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/32\">",
"      Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010; 16:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/33\">",
"      Law ST, Ma KM, Li KK. The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. Lupus 2012; 21:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/34\">",
"      Perednia DA, Curosh NA. Lupus-associated protein-losing enteropathy. Arch Intern Med 1990; 150:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5928/abstract/35\">",
"      Mok CC, Ying KY, Mak A, et al. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine. Rheumatology (Oxford) 2006; 45:425.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4672 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5928=[""].join("\n");
var outline_f5_50_5928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H742100\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DYSPHAGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PEPTIC ULCER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MESENTERIC VASCULITIS AND INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PANCREATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lupoid hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROTEIN-LOSING ENTEROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H742100\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=related_link\">",
"      Predicting the severity of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5929="Assessment of sleep disorders in children";
var content_f5_50_5929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of sleep disorders in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Merrill S Wise, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5929/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/50/5929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of sleep problems in children is important because a growing body of evidence suggests a link between sleep disorders and physical, cognitive, emotional, and social development. Children with neurodevelopmental problems, learning differences, or behavior problems may be at heightened risk for sleep problems compared with the general pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatricians, pediatric subspecialists, and other healthcare practitioners are in an ideal position to identify sleep problems and disorders in children. Parents may not volunteer information about their child's sleep, or they may not appreciate the potential relationship between sleep problems and daytime behavior. For these reasons, clinicians should incorporate questions about sleep into routine health assessment for children of all ages. Sleep problems present most commonly in the outpatient setting, but the hospitalized child may develop sleep problems during an acute illness, or chronic sleep disorders may come to medical attention during hospitalization.",
"   </p>",
"   <p>",
"    This topic review will discuss the approach to taking a structured sleep history, describe specific sleep problems that may present during childhood, and explain indications for further diagnostic testing. The underlying physiology of sleep in children, and evaluation and management of some common sleep disorders are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=see_link\">",
"     \"Sleep physiology in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link\">",
"     \"Behavioral sleep problems in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link\">",
"     \"Sleepwalking and other parasomnias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PEDIATRIC SLEEP MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric sleep medicine is a multidisciplinary field that includes clinicians in general pediatrics as well as subspecialists in child neurology, psychiatry, psychology, otolaryngology, pulmonary medicine, and development.",
"   </p>",
"   <p>",
"    Although sleep disorders may be phenomenologically similar between adults and children, several important differences exist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/5\">",
"     5",
"    </a>",
"    ]. The presentation, natural history, and response to treatment may differ considerably between adults and children. As an example, obstructive sleep apnea syndrome is well recognized in adults and children. However, in contrast to adults, most pediatric patients are not obese, boys and girls are equally affected, and some children present with daytime attentional or behavioral problems rather than overt sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even within the pediatric age group, the clinical manifestations of sleep problems may vary by age and developmental level. For example, sleepiness in the school aged child may be subtle and variable in comparison to adult manifestations. The child with excessive sleepiness may exhibit motor overactivity, inattentiveness, irritability, or oppositional behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Sleep problems such as difficulty initiating or maintaining sleep (insomnia) may co-exist with anxiety or depression in the adolescent, and may worsen certain medical or psychiatric problems.",
"   </p>",
"   <p>",
"    Sleep and sleep disorders in children are strongly influenced by cultural factors, parental expectations, and parental responses. When responding to a preschool child with stalling behavior at bedtime, inexperienced parents may inadvertently promote the behavior, while more experienced parents quickly establish a consistent response that extinguishes the unwanted behavior. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Behavioral contributors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link\">",
"     \"Behavioral sleep problems in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification of sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Sleep Disorders (ICSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9\">",
"     9",
"    </a>",
"    ] provides a diagnostic and coding manual for recognized sleep disorders. The classification provides a systematic review of the essential features, diagnostic criteria, prevalence, predisposing factors, pathology, complications, and polysomnographic findings associated with each recognized sleep disorder. The classification scheme is summarized in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"     \"Classification of sleep disorders\"",
"    </a>",
"    .) In addition, the ICSD now includes the new category, Behavioral Insomnia of Childhood that includes sleep onset association and limit-setting subtypes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link&amp;anchor=H2#H2\">",
"     \"Behavioral sleep problems in children\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Academy of Sleep Medicine (AASM) and Sleep Research Society (SRS) are active professional organizations dedicated to the advancement of sleep medicine and related research. The AASM web site (",
"    <a class=\"external\" href=\"file://www.aasmnet.org/\">",
"     www.aasmnet.org",
"    </a>",
"    ) and SRS web site (",
"    <a class=\"external\" href=\"file://www.sleepresearchsociety.org/\">",
"     www.sleepresearchsociety.org",
"    </a>",
"    ) provide information on professional standards, education and training, accreditation, publications, research opportunities, and patient resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACH TO THE SLEEP HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough sleep and medical history, guided by an understanding of normal sleep physiology, provides the foundation for diagnosis and management of sleep problems. Reviewing a child's sleep history may be time-consuming. However, this investment of time is greatly appreciated by parents, and the process often provides valuable information not available through any other means. A variety of checklists and questionnaires are available and may supplement the history. As an example, BEARS is a screening acronym that prompts a clinician to inquire about five sleep areas (B=Bedtime Issues, E=Excessive daytime sleepiness, A=Night awakenings, R=Regularity and duration of sleep, S=Snoring) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/10\">",
"     10",
"    </a>",
"    ]. This type of screen can help identify patients who should be evaluated with a more detailed sleep history. There is no substitute for a thorough sleep and medical history by a knowledgeable clinician.",
"   </p>",
"   <p>",
"    The sleep history is most contributory when it is structured, detailed, and systematic. The clinician should evaluate the",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    schedule, difficulties initiating or maintaining sleep, abnormal movements or behavior during sleep, and daytime accompaniments (eg, sleepiness, inattentiveness, or irritability). The history should include details about the duration and frequency of the problem, temporal profile of onset (abrupt, gradual, intermittent), and degree of variability from night to night. The clinician should note what interventions or strategies have been tried and whether medications have been used.",
"   </p>",
"   <p>",
"    Because parents are generally asleep during the night, they may struggle to provide a full history. They may witness only portions of nighttime events, and they may have limited ability to provide a history due to inexperience, anxiety, or lack of sophistication. More experienced or organized parents often generate diaries or logs of sleep problems, and the widespread availability of home video cameras has increased the opportunity for physicians to visualize episodes of abnormal movement or behavior.",
"   </p>",
"   <p>",
"    Completion of a sleep log during the two weeks prior to evaluation may provide important information regarding the",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    pattern and nocturnal events. The log should include bed time, time of sleep onset, awakenings, rise time, nocturnal events, feeding pattern, naps, perceived quality of sleep, degree of alertness or sleepiness during the day, and observations regarding nocturnal events and medical or psychological stressors. The child&rsquo;s sleep patterns can then be compared to typical sleep patterns for his or her age group (",
"    <a class=\"graphic graphic_figure graphicRef82604 \" href=\"UTD.htm?14/0/14351\">",
"     figure 1",
"    </a>",
"    ), although it should be recognized that the average sleep time of children in a given age group varies by as much as two hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=see_link&amp;anchor=H3#H3\">",
"     \"Sleep physiology in children\", section on 'Maturation of sleep architecture'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chief sleep complaint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history begins with asking the parent or child to identity the chief complaint related to sleep. Despite the many ways children may experience sleep problems, most complaints can be distilled into one (or more) of four categories [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Difficulty initiating or maintaining sleep",
"     </li>",
"     <li>",
"      Excessive daytime sleepiness",
"     </li>",
"     <li>",
"      Snoring or other breathing problems during sleep",
"     </li>",
"     <li>",
"      Abnormal movements or behaviors during sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sleep history should always assess for difficulties in each of these areas. However, the emphasis of the history depends on the nature of the chief complaint, as detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Concomitant medical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the child with sleep problems should also include a thorough medical review with attention to possible neurodevelopmental or medical problems. Chronic conditions such as reactive airways disease, gastroesophageal reflux, congenital heart disease, arthritis, and other causes of chronic pain may predispose the child to sleep problems. Neurological disorders such as cerebral palsy, mental retardation, autism and related disorders, blindness, and conditions with poor oropharyngeal function are associated with elevated risk for sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/1\">",
"     1",
"    </a>",
"    ]. Both behavioral sleep problems and obstructive sleep apnea (OSA) are associated with attention deficit hyperactivity disorder (ADHD) and other special educational needs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/12\">",
"     12",
"    </a>",
"    ]. In the case of OSA, the sleep disorder probably causes some of the inattentive, hyperactive, or disruptive daytime behavior and the educational problems. In other cases, such as ADHD, the behavioral sleep problems appear to be a consequence of the underlying psychiatric disorder, or of medications used to improve daytime behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medication history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medication history is important because sleep physiology is affected by many of the medications used in pediatrics.",
"   </p>",
"   <p>",
"    Medications with sedating effects can cause daytime sleepiness. These include certain anti-histamines, anti-depressants (especially the tricyclic compounds), benzodiazepines and anti-seizure medications (especially barbiturates and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    ), and alpha-adrenergic agonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selective serotonergic reuptake inhibitors (SSRIs) decrease the quantity of REM sleep and prolong the latency to REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/17\">",
"     17",
"    </a>",
"    ]. Following abrupt withdrawal of the SSRIs, rebound REM sleep or other REM phenomena may occur.",
"   </p>",
"   <p>",
"    Stimulant medications, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , prolong latency to sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/17\">",
"     17",
"    </a>",
"    ]. Exposure to caffeine also may affect sleep latency and continuity; the child and caregiver should be asked about consumption of caffeine-containing beverages (eg, colas, coffee, and tea).",
"   </p>",
"   <p>",
"    Ethanol shortens latency to sleep and decreases the quantity of REM sleep in the first one-half of the sleep period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFICULTY INITIATING OR MAINTAINING SLEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A useful way to gather history on a child with difficulty initiating sleep is to review the child's pattern of activity, hour by hour, from the point of arrival home from school or daycare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Behavioral contributors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleeplessness, or more specifically difficulty initiating or maintaining sleep (insomnia), in children often has behavioral roots. The problem can be clarified by evaluating the sleep schedule, sleeping environment, and bedtime routines. When problems are identified, the provider can advise the parent on how to modify the routine to improve sleep habits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link\">",
"     \"Behavioral sleep problems in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-sleep activities &mdash; The clinician should record specific times of activities, including periods of exercise or competitive sports, homework times, dinner time, and whether television viewing or computer game playing occurs. One study suggests that sedentary activity during the day is associated with increased sleep latency (ie, more difficulty falling asleep), whereas physical activity reduces sleep latency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/18\">",
"       18",
"      </a>",
"      ]. The effects of sedentary activities or sports also depend on the timing of the activities, and vary among individual children.",
"     </li>",
"     <li>",
"      Bedtime routine &mdash; The clinician should discuss the bedtime routine, including the consistency with which parents adhere to schedules, how stalling is addressed, and where the child falls asleep. Other important features are the circumstances present when the child falls asleep, whether one or both parents are present as the child falls asleep, and whether stimulating activities are readily available in the sleep environment (such as television sets or computers in the bedroom). The presence of other siblings in the bedroom, or other disruptive environmental circumstances (eg, a loud or unsafe neighborhood) should be noted.",
"     </li>",
"     <li>",
"      Response to nighttime awakenings &mdash; When children experience nighttime awakenings, the parents' response can promote or extinguish the behavior. As an example, excessive parental attention in response to nighttime awakenings (including routinely allowing the child to switch beds) may perpetuate the problem. The clinician should assess whether the parents' response to nighttime awakenings is likely to reinforce the behavior, and should offer advice on how to reverse this pattern. For some infants and toddlers, habitual nighttime feedings may disrupt sleep and are often unnecessary. Clinicians should inquire about nighttime feedings and offer guidance on eliminating these when appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other contributors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial history &mdash; Psychosocial dysfunction may cause or present as a sleeping problem. Conversely, children's sleeping problems can contribute to household and marital stress. The clinician should probe the psychosocial history, including the presence of marital discord, use of alcohol or drugs by those in the home, and the possibility of child abuse. In some cases, it may be necessary to interview the child alone to get a reliable history.",
"     </li>",
"     <li>",
"      Anxiety or depression &mdash; Anxiety (including separation anxiety) and depression are common causes of insomnia in children. All children have fears at some point in their lives, and these may interfere with sleep. If the fears are persistent and consistently interfere with functioning (ie, sleep), evaluation for a specific phobia or generalized anxiety disorder may be warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"       \"Overview of fears and specific phobias in children\"",
"      </a>",
"      .) In addition to insomnia, symptoms of depression include depressed or irritable mood, diminished interest or pleasure (anhedonia), change in appetite or weight status, psychomotor agitation or retardation (eg, talking or moving more slowly than is usual for them), fatigue or loss of energy, feelings of worthlessness or guilt, impaired concentration, or recurrent thoughts of death or suicide. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concomitant medical problems &mdash; The clinician should identify chronic medical problems that may influence sleep, including chronic or recurrent pain, symptoms suggestive of gastroesophageal reflux, breathing problems during wakefulness or sleep, and the medication history. Such medical problems may disrupt sleep because of discomfort or because of medical interventions (eg, medications, breathing treatments, or feeds) that are given during the night. Some medications, including stimulants used for attention deficit disorder, may affect sleep latency and continuity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Medication history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXCESSIVE DAYTIME SLEEPINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For evaluation of the child with excessive daytime sleepiness, the history is directed at identification of potential causes. If parents are not aware of age-appropriate norms for nighttime sleep and daytime napping (",
"    <a class=\"graphic graphic_figure graphicRef82604 \" href=\"UTD.htm?14/0/14351\">",
"     figure 1",
"    </a>",
"    ), they may fail to recognize poor sleep hygiene or chronic sleepiness in their child. Furthermore, a sleepy child may not appear sleepy to parents or clinicians. Instead, these observers may notice attentional difficulties due to unsuspected sleepiness, hyperactivity secondary to the child's efforts to stay awake, or aggressive and disruptive behavior that reflects inability of a sleep-deprived frontal cortex to regulate emotion normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes of sleepiness include insufficient nocturnal sleep, inadequate sleep hygiene, and medication side effects.",
"   </p>",
"   <p>",
"    Less common but important causes include narcolepsy, idiopathic hypersomnia, periodic limb movement disorder, and a variety of toxic, endocrine, and metabolic problems.",
"   </p>",
"   <p>",
"    Obstructive sleep apnea can present with complaints of daytime sleepiness or associated behavioral problems; complaints of excessive snoring or abnormal breathing during sleep are usually, but not always present. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Obstructive sleep apnea'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Narcolepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with narcolepsy may experience cataplexy (sudden bilateral loss of tone, often precipitated by a sudden emotion such as laughter), sleep paralysis, or hypnagogic hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/8,19-21\">",
"     8,19-21",
"    </a>",
"    ]. Children with narcolepsy often experience severe sleepiness, including falling asleep during meal times and conversation, sports events, or social activities. Academic failure is common. Cataplexy should be differentiated from atonic seizures, syncope, vestibular disorders, transient ischemic attacks, and behaviorally based loss of postural tone.",
"   </p>",
"   <p>",
"    The diagnostic evaluation for narcolepsy includes a focused history and physical examination, polysomnography and multiple sleep latency test (MSLT). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Multiple sleep latency test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Narcolepsy in adults is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=see_link\">",
"     \"Clinical features and diagnosis of narcolepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Underlying medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chronic disease, including anemia, malignancy, or metabolic problems may exhibit excessive sleepiness. Other sources of hypersomnia include post-traumatic hypersomnia, recurrent hypersomnia (Kleine-Levin syndrome), menstruation-associated hypersomnia, pregnancy-associated hypersomnia, and circadian rhythm disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9,22,23\">",
"     9,22,23",
"    </a>",
"    ]. Acute hypersomnia may occur in association with meningitis, encephalitis, or certain toxic exposures (eg, carbon monoxide and heavy metals). Sleepiness may occur in association with increased intracranial pressure due to hydrocephalus or mass lesions in the region of the third ventricle or posterior hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/7\">",
"     7",
"    </a>",
"    ]. Headaches, diplopia, or papilledema may be present, and further evaluation with neuroimaging is indicated for children with suspected mass lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of sleep disorders\", section on 'Hypersomnia of central origin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sleepiness should be differentiated from chronic fatigue, which often involves somatic complaints, such as weakness or easy fatigability, malaise, nonrestorative sleep patterns, and emotional disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SNORING OR BREATHING PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep-related breathing disorders may cause snoring and other sounds while sleeping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) in children typically presents with complaints of snoring or other sounds, such as snorting or gasping. Daytime behavioral problems can be presenting symptoms, and excessive daytime sleepiness is often evident on specific questioning. Children whose initial screening reveals these issues, or those with marked adenotonsillar hypertrophy or obesity, deserve a more detailed clinical evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Polysomnography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children with upper airway obstruction, snoring may occur more frequently in the supine position. When the airway obstruction is severe, the snoring often occurs in any sleeping position. However, in contrast to adults with OSA, children with OSA may not snore, and they may not experience recurrent awakenings or arousals with episodes of obstruction. Because upper airway obstruction is often worse during REM sleep, episodes of snoring, gasping, apnea, and sudden arousal during airway obstruction are often observed more frequently in the final one-third of the night [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=see_link&amp;anchor=H6#H6\">",
"     \"Sleep physiology in children\", section on 'Association of sleep disorders with sleep states'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nighttime symptoms of OSA may include paradoxical chest-abdominal movements, retractions, observed apneas, restless sleep, excessive sweating, or cyanosis. Nocturnal enuresis occurs more frequently in children with OSA than in children without OSA, and enuresis may improve in association with treatment of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Daytime symptoms may include nasal obstruction, mouth breathing or other signs of adenotonsillar hypertrophy, poor attentiveness, irritability or other behavior problems, or daytime sleepiness.",
"   </p>",
"   <p>",
"    Children with severe OSA may sleep in the upright or semi-upright position to maintain upper airway patency. Severe forms may be associated with failure to thrive, cor pulmonale, or delayed development [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/21\">",
"     21",
"    </a>",
"    ]. Upon questioning, parents may acknowledge staying awake during the night to monitor whether their child was breathing, and to stimulate the child to make him or her breathe during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/21,26\">",
"     21,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ABNORMAL MOVEMENTS OR BEHAVIORS DURING SLEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal movements or behaviors may be observed in a variety of sleep disorders, including respiratory disturbance, parasomnias, and nocturnal seizures. Nocturnal events associated with high amplitude movements may present a significant risk of injury to the child, and protective measures may be required.",
"   </p>",
"   <p>",
"    A thorough history is adequate in most cases for characterization of nocturnal events and establishing a diagnosis. Recordings of representative clinical events with a home video camera may provide useful information. In some cases, additional diagnostic evaluation, such as electroencephalography (EEG) or prolonged",
"    <span class=\"nowrap\">",
"     EEG/video/polygraphic",
"    </span>",
"    monitoring is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nocturnal seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal seizures may be generalized or partial (focal) in character. Temporal and frontal lobe seizures are the most common localization-related epilepsies in sleep. Events are highly stereotypic (ie, the same behavior pattern recurs), and are often brief but frequent during the night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=see_link\">",
"     \"Benign partial epilepsies of childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Seizures versus parasomnias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiation of nocturnal seizures from parasomnias is important since treatment of the two conditions is different, and because identification of seizures may require additional evaluation such as neuroimaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/27\">",
"     27",
"    </a>",
"    ]. Both parasomnias and nocturnal complex partial seizures may be associated with altered behavior and responsiveness, and automatisms; attempts to awaken a child during a NREM parasomnia may precipitate a lengthy period of confusion (ie, partial arousal) reminiscent of a post-ictal state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H27172788#H27172788\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Disorders of arousal from non-rapid eye movement (NREM) sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A key differentiating feature involves the time of occurrence in the sleep period. NREM parasomnias (eg, sleep walking, sleep terrors, and confusional arousals) typically occur in association with deeper stages of NREM sleep in the first one-third of the night [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. REM sleep phenomena (eg, nightmares, sleep paralysis, and REM sleep behavior disorder) tend to occur in the final one-third of the night, when REM sleep predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Nocturnal seizures may occur during any stage of sleep but are observed most frequently in the transition into non-REM sleep, or upon arousal from sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=see_link&amp;anchor=H6#H6\">",
"     \"Sleep physiology in children\", section on 'Association of sleep disorders with sleep states'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H27172825#H27172825\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Differential diagnosis of arousal parasomnias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Periodic limb movement disorder and restless leg syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic limb movement disorder (nocturnal myoclonus) is characterized by periodic episodes of repetitive and highly stereotypic limb movements during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9\">",
"     9",
"    </a>",
"    ]. The movements usually involve extension of the great toe and partial flexion of the ankle, knee, and sometimes hip. When these movements are associated with repetitive partial arousals or awakenings, sleep is fragmented. Although this problem was once thought to begin in adulthood, subsequent investigations have indicated that these movements also occur in children and that an association exists between periodic limb movements and daytime problems, including diminished attentiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is significant overlap between periodic limb movement disorder and restless leg syndrome in both children and adults. Children with restless legs syndrome often have depressed serum ferritin levels, indicating reduced iron stores, and in this case the disorder may improve with iron supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"     \"Restless legs syndrome and periodic limb movement disorder in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodic limb movements must be differentiated from sleep starts (hypnic jerks), benign neonatal sleep myoclonus, myoclonic seizures, and the limb jerks associated with sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H17023943#H17023943\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Hypnic starts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Benign neonatal sleep myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Rhythmic movement disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythmic movement disorder consists of stereotyped repetitive movements involving large muscle groups, usually of the head and neck. The movements often begin immediately prior to sleep onset and are sustained into light sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/9\">",
"     9",
"    </a>",
"    ]. Examples include repetitive head-banging, head rolling, and body rocking or rolling. Rhythmic humming or chanting may occur with these movements. This group of movements occurs typically in the toddler years, and movements often resolve gradually by the school years. The distinctive character of rhythmic movement disorder allows a clinical diagnosis in most cases, although differentiation from epileptic seizures may be required in rare cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H17023639#H17023639\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Rhythmic movement disorder'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Obstructive sleep apnea'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is directed towards identification of causes of sleep disorders, or sequelae associated with sleep pathology.",
"   </p>",
"   <p>",
"    General observations include the child's level of alertness (including possible fluctuations in degree of alertness) during the examination. Repetitive yawning, droopy eyelids, blank facial expression, frequent changes in position, overactivity, and irritability may indicate excessive sleepiness.",
"   </p>",
"   <p>",
"    The general examination should include assessment for dysmorphic features such as those associated with Down syndrome, Prader-Willi syndrome, craniofacial anomalies, and microcephaly or macrocephaly. Inspection for signs of scoliosis and neuromuscular disease should be performed. Developmental milestones should be evaluated. Evaluation of growth parameters may indicate failure to thrive, evolving obesity, or obesity.",
"   </p>",
"   <p>",
"    Examination of the oropharynx may reveal evidence of tonsillar or adenoidal hypertrophy, an abnormally small upper airway, mandibular hypoplasia, retrognathia, or bulbar dysfunction. Bulbar dysfunction can manifest with decreased or absent gag reflex, poor movement of the soft palate, or swallowing problems. Persistent mouth breathing or noisy breathing may suggest nasal obstruction. Clubbing, cyanosis, or edema may suggest heart failure. Lung examination may suggest chronic lung disease or reactive airways disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POLYSOMNOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysomnography (PSG) typically consists of an all-night recording performed in the sleep laboratory in order to characterize sleep architecture and sleep pathology. A number of physiological parameters are measured, including sleep stages (characterized using a combination of EEG, eye movements, and muscle tone), respiratory function (including air flow at the nose and mouth, respiratory movements of the chest and abdomen, and oximetry), electrocardiogram (EKG), limb movements, a microphone to detect sounds such as snoring or vocalizations, and video tape to characterize movements or behaviors during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/33\">",
"     33",
"    </a>",
"    ]. A standardized scoring manual provides guidelines and criteria for analysis of polysomnography in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/34\">",
"     34",
"    </a>",
"    ]. Specific guidelines are also available for infants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Polysomnography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory-based polysomnography performed by a sleep technologist is indicated for the following purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for a sleep-related breathing disorder (eg, obstructive sleep apnea)",
"     </li>",
"     <li>",
"      Assessment for narcolepsy (in conjunction with a multiple sleep latency test) (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Multiple sleep latency test'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Assessment for periodic limb movement disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"       \"Restless legs syndrome and periodic limb movement disorder in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Titration of continuous positive airway pressure (CPAP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polysomnography also may be indicated for evaluation of [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/36\">",
"     36",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with neuromuscular disorders and sleep-related symptoms",
"     </li>",
"     <li>",
"      A parasomnia associated with clinical suspicion for a sleep-related breathing disorder or periodic limb movement disorder",
"     </li>",
"     <li>",
"      Children suspected to have restless legs syndrome, when additional supportive data (demonstration of periodic leg movements) are desired to help confirm the diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polysomnography with an expanded EEG montage may be indicated for evaluation of [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with suspected sleep-related epilepsy when the initial clinical evaluation and standard EEG are inconclusive, to help distinguish the disorder from a parasomnia",
"     </li>",
"     <li>",
"      Patients with an atypical or potentially injurious parasomnia, to confirm the diagnosis and assess for sleep-related epilepsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polysomnography is not routinely indicated for evaluation of difficulty initiating or maintaining sleep (insomnia), circadian rhythm disorders, uncomplicated parasomnias, chronic lung disease, depression, restless legs syndrome, bruxism, or behaviorally based sleep problems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MULTIPLE SLEEP LATENCY TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multiple Sleep Latency Test (MSLT) is an objective, in-laboratory assessment for excessive daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/38\">",
"     38",
"    </a>",
"    ]. This test is based on the concept that the speed with which one falls asleep is an indication of the severity of sleepiness. The MSLT is also used more specifically to assess for narcolepsy when the clinical history suggests this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link&amp;anchor=H4#H4\">",
"     \"Quantifying sleepiness\", section on 'Multiple sleep latency test (MSLT)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The MSLT is performed following nocturnal PSG and consists of five nap opportunities at two-hour intervals across the day. With each nap opportunity the patient is placed in a dimly lit, quiet room in the recumbent position, and the subject is given instructions to \"lie quietly, close your eyes and try to fall asleep.\" The latency until sleep onset is measured for each nap opportunity, and the patient is allowed to sleep for 15 minutes after sleep-onset. A maximum of 20 minutes is permitted for the nap attempt. If no sleep occurs, the sleep latency for that nap is considered to be 20 minutes when the mean sleep latency is calculated.",
"   </p>",
"   <p>",
"    The mean sleep latency across all nap opportunities represents a measure of the subject's ability to fall asleep in an environment conducive to sleep. Adults who are not excessively sleepy fall asleep in 10 to 20 minutes under these circumstances, whereas mean sleep latency values less than five minutes are considered to indicate pathological sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5929/abstract/38\">",
"     38",
"    </a>",
"    ]. Normative values in children are less well defined than in adults, but normal school-aged children typically remain awake throughout each 20 minute nap opportunity, or demonstrate a mean sleep latency in the 15 to 20 minute range.",
"   </p>",
"   <p>",
"    Individuals with narcolepsy or severe sleep deprivation typically fall asleep in less than five minutes, and sometimes as quickly as one or two minutes. Individuals with narcolepsy generally experience two or more naps with entry into REM sleep as a manifestation of an abnormal propensity for REM sleep. However, abnormal entry into REM sleep may occur in other disorders associated with fragmented nocturnal sleep, such as obstructive sleep apnea, sleep deprivation, and as a rebound phenomenon after REM suppressing medications are stopped abruptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       \"Patient information: Daytime sleepiness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/9/17554?source=see_link\">",
"       \"Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=see_link\">",
"       \"Patient information: Sleepwalking in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disorders in children can impair academic function and daytime behavior. Clinicians should incorporate questions about sleep into their routine health assessment of children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A structured sleep history assesses the",
"      <span class=\"nowrap\">",
"       sleep/wake",
"      </span>",
"      schedule, difficulties initiating or maintaining sleep, abnormal movements or behavior during sleep, and daytime accompaniments (eg, sleepiness, inattentiveness, or irritability). The history should include details about the duration and frequency of the problem, temporal profile of onset (abrupt, gradual, intermittent), and degree of variability from night to night. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach to the sleep history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Difficulties initiating or maintaining sleep (sleeplessness or insomnia) in children are most often behavioral. These issues can be identified by evaluating the sleep schedule, sleeping environment, and bedtime routines. Other causes or contributors include psychosocial stressors, underlying medical problems, and anxiety or depression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Difficulty initiating or maintaining sleep'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link\">",
"       \"Behavioral sleep problems in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common causes of daytime sleepiness include insufficient nocturnal sleep as compared to the average sleep requirements for the age group (",
"      <a class=\"graphic graphic_figure graphicRef82604 \" href=\"UTD.htm?14/0/14351\">",
"       figure 1",
"      </a>",
"      ), inadequate sleep hygiene, and medication side effects. Less common but important causes include narcolepsy, idiopathic hypersomnia and periodic limb movement disorder. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Excessive daytime sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea in children typically presents with snoring, other noisy breathing, daytime behavioral problems, or excessive daytime sleepiness. If these symptoms are present, or if a child has significant adenotonsillar hypertrophy or obesity, a more detailed clinical evaluation is warranted. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Obstructive sleep apnea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal movements or behaviors may be observed in a variety of sleep disorders, including parasomnias and nocturnal seizures. As compared with nocturnal seizures, NREM parasomnias more typically occur during the first part of the night, are less likely to have stereotypic behaviors, and are more likely to recur during the same night. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Abnormal movements or behaviors during sleep'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Nocturnal seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restless legs syndrome and periodic limb movements in sleep are relatively common in children and are associated with diminished attentiveness. Children with restless leg syndrome often have depressed serum ferritin levels, indicating reduced iron stores, and in this case the disorder may improve with iron supplementation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Periodic limb movement disorder and restless leg syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some children, evaluation with overnight polysomnography may be required to confirm a specific sleep disorder (eg, obstructive sleep apnea or narcolepsy) or to titrate positive airway pressure. Polysomnography is not routinely indicated for children with insomnia, circadian rhythm sleep disturbances, uncomplicated parasomnias, or behavioral sleep problems. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Polysomnography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Multiple Sleep Latency Test (MSLT) is an objective, in-laboratory assessment of daytime sleepiness. It is often used in conjunction with a nocturnal polysomnogram to evaluate patients suspected of having narcolepsy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Multiple sleep latency test'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Brown LW, Maistros P, Guilleminault C. Sleep in children with neurological problems. In: Principles and Practice of Sleep Medicine in the Child, Ferber R, Kryger M (Eds), WB Saunders, Philadelphia 1995. p.135.",
"    </li>",
"    <li>",
"     Okawa M, Sasaki H. Sleep disorders in mentally retarded and brain-impaired children. In: Sleep and its Disorders in Children, Guilleminault C (Ed), Raven Press, New York 1987. p.269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/3\">",
"      Picchietti DL, England SJ, Walters AS, et al. Periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. J Child Neurol 1998; 13:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/4\">",
"      Chervin RD, Dillon JE, Bassetti C, et al. Symptoms of sleep disorders, inattention, and hyperactivity in children. Sleep 1997; 20:1185.",
"     </a>",
"    </li>",
"    <li>",
"     Ferber R. Introduction: Pediatric sleep disorders medicine. In: Principles and Practice of Sleep Medicine in the Child, Ferber R, Kryger M (Eds), WB Saunders, Philadelphia 1995. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/6\">",
"      Owens J, Opipari L, Nobile C, Spirito A. Sleep and daytime behavior in children with obstructive sleep apnea and behavioral sleep disorders. Pediatrics 1998; 102:1178.",
"     </a>",
"    </li>",
"    <li>",
"     Sheldon SH, Spire JP, Levy HB. Disorders of excessive somnolence. In: Pediatric Sleep Medicine, Sheldon SH, Spire JP, Levy HB (Eds), WB Saunders, Philadelphia 1992. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/8\">",
"      Wise MS. Childhood narcolepsy. Neurology 1998; 50:S37.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/10\">",
"      Owens JA, Dalzell V. Use of the 'BEARS' sleep screening tool in a pediatric residents' continuity clinic: a pilot study. Sleep Med 2005; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     Naylor MW, Aldrich MS. Approach to the patient with disordered sleep. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, 1994. p.413.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/12\">",
"      Bonuck K, Rao T, Xu L. Pediatric sleep disorders and special educational need at 8 years: a population-based cohort study. Pediatrics 2012; 130:634.",
"     </a>",
"    </li>",
"    <li>",
"     Nicholson AN. Pharmacology of sleep and wakefulness: An introduction. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.331.",
"    </li>",
"    <li>",
"     Gaillard JM. Benzodiazepines and GABA-ergic transmission. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.349.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/15\">",
"      Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982; 2:14.",
"     </a>",
"    </li>",
"    <li>",
"     Ortho-McNeal Pharmaceuticals. Topiramate package insert.",
"    </li>",
"    <li>",
"     Nicholson AN, Bradley CM, Pascoe PA. Medications: Effects on sleep and wakefulness. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/18\">",
"      Nixon GM, Thompson JM, Han DY, et al. Falling asleep: the determinants of sleep latency. Arch Dis Child 2009; 94:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/19\">",
"      Guilleminault C, Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998; 43:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/20\">",
"      Kotagal S. Narcolepsy in children. Semin Pediatr Neurol 1996; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     Carroll JL, Loughlin GM. Obstructive sleep apnea syndrome in infants and children: clinical features and pathophysiology. In: Principles and Practice of Sleep Medicine in the Child, Ferber R, Kryger M (Eds), WB Saunders, Philadelphia 1995. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/22\">",
"      Huang YS, Lakkis C, Guilleminault C. Kleine-Levin syndrome: current status. Med Clin North Am 2010; 94:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/23\">",
"      Lisk DR. Kleine-Levin syndrome. Pract Neurol 2009; 9:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/24\">",
"      Barone JG, Hanson C, DaJusta DG, et al. Nocturnal enuresis and overweight are associated with obstructive sleep apnea. Pediatrics 2009; 124:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/25\">",
"      Basha S, Bialowas C, Ende K, Szeremeta W. Effectiveness of adenotonsillectomy in the resolution of nocturnal enuresis secondary to obstructive sleep apnea. Laryngoscope 2005; 115:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/26\">",
"      Carroll JL, McColley SA, Marcus CL, et al. Reported symptoms of childhood obstructive sleep apnea syndrome (OSA) vs primary snoring. Am Rev Respir Dis 1992; 145:A177.",
"     </a>",
"    </li>",
"    <li>",
"     Wise MS. Differential diagnosis of paroxysmal nocturnal events in infants and children. In: Sleep and Epilepsy: The Clinical Spectrum, Bazil CW, Malow BA, Sammaritano MR (Eds), Elsevier Science, Amsterdam 2002. p.339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/28\">",
"      Gastaut H, Broughton RJ. A clinical and polygraphic study of episodic phenomena during sleep. Biol Psychiatry 1965; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     Keefauver SP, Guilleminault C. Sleep terrors and sleep walking. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.567.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/30\">",
"      Fisher C, Byrne J, Edwards A, Kahn E. A psychophysiological study of nightmares. J Am Psychoanal Assoc 1970; 18:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/31\">",
"      Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9:293.",
"     </a>",
"    </li>",
"    <li>",
"     Sammaritano MR, Therrien M. Epilepsy and the \"sleep-wake cycle\". In: Sleep and Epilepsy: the Clinical Spectrum, Bazil CW, Malow BA, Sammaritano MR (Eds), Elsevier Science, Amsterdam 2002. p.145.",
"    </li>",
"    <li>",
"     Carskadon MA, Rechtschaffen A. Monitoring and staging human sleep. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, 1994. p.943.",
"    </li>",
"    <li>",
"     Iber C, Ancoli-Israel S, Chesson AL, et al. The AASM Manual for the Scoring of Sleep and Associated Events, American Academy of Sleep Medicine, West Chester, IL 2007.",
"    </li>",
"    <li>",
"     A manual of standardized terminology, techniques and criteria for scoring of states of sleep and wakefulness in newborn infants, Anders T, Emde R, Parmelee AH (Eds), UCLA Brain Information Service, NINDS Neurological Information Network, Los Angeles 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/36\">",
"      Aurora RN, Lamm CI, Zak RS, et al. Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children. Sleep 2012; 35:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/37\">",
"      Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5929/abstract/38\">",
"      Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6357 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5929=[""].join("\n");
var outline_f5_50_5929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PEDIATRIC SLEEP MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACH TO THE SLEEP HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chief sleep complaint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Concomitant medical problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medication history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFICULTY INITIATING OR MAINTAINING SLEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Behavioral contributors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other contributors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXCESSIVE DAYTIME SLEEPINESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Underlying medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SNORING OR BREATHING PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ABNORMAL MOVEMENTS OR BEHAVIORS DURING SLEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nocturnal seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Seizures versus parasomnias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Periodic limb movement disorder and restless leg syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Rhythmic movement disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POLYSOMNOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MULTIPLE SLEEP LATENCY TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6357|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/0/14351\" title=\"figure 1\">",
"      Typical sleep time in children by age group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=related_link\">",
"      Behavioral sleep problems in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=related_link\">",
"      Overview of fears and specific phobias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/9/17554?source=related_link\">",
"      Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=related_link\">",
"      Patient information: Sleepwalking in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=related_link\">",
"      Restless legs syndrome and periodic limb movement disorder in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=related_link\">",
"      Sleep physiology in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5930="Coronary artery patency and outcome after myocardial infarction";
var content_f5_50_5930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery patency and outcome after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Richard C Becker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Carey Kimmelstiel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/50/5930/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/50/5930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is widely accepted that the likelihood of death after myocardial infarction (MI) correlates inversely with left ventricular performance. In turn, the degree of left ventricular dysfunction is determined by the extent of myocardial necrosis or infarct size. Thus, pump failure and increased mortality result when the infarct is large and ventricular compromise is severe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prompt and sustained coronary arterial patency has repeatedly been found to limit infarct size. Among patients with an acute ST elevation (Q wave) MI, over 90 percent have complete occlusion of the culprit artery. Patency can be achieved by fibrinolysis, primary percutaneous coronary intervention (PCI), or a combination of both modalities. In addition, there are many factors (hemodynamic, anatomic, cellular) that influence coronary artery patency regardless of the technique used (",
"    <a class=\"graphic graphic_figure graphicRef52322 \" href=\"UTD.htm?35/59/36787\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMI FLOW GRADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of perfusion in the infarct-related artery (IRA) is typically described by the TIMI flow grade:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIMI 0 refers to the absence of antegrade flow beyond a coronary occlusion.",
"     </li>",
"     <li>",
"      TIMI 1 flow is faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete.",
"     </li>",
"     <li>",
"      TIMI 2 flow is delayed or sluggish antegrade flow with complete filling of the distal territory.",
"     </li>",
"     <li>",
"      TIMI 3 flow is normal flow which fills the distal coronary bed completely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPEN VESSEL HYPOTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1940s, the possible relationship between a patent IRA, myocardial damage, and mortality was first advanced in the open vessel hypothesis. This theory holds that early reperfusion results in myocardial salvage, preserves ventricular performance, and is ultimately responsible for improved patient survival.",
"   </p>",
"   <p>",
"    The foundation for the open vessel hypothesis came from the demonstration in dogs that the extent of infarction was affected by the duration of coronary arterial occlusion. As a result of this and subsequent investigations, the clinical importance of a patent, as opposed to an occluded infarct-related coronary artery, is now widely accepted.",
"   </p>",
"   <p>",
"    The impact of reperfusion of the infarct-related artery with either fibrinolysis or angioplasty on survival may be due to both time-dependent and time-independent mechanisms. Time independent mechanisms possibly responsible for improved survival include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/3-15\">",
"     3-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effects on post-MI left ventricular remodeling, such as a reduction in infarction expansion, ventricular dilatation, and aneurysm formation, resulting in better left ventricular function and a smaller wall motion abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improvement in diastolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Effects on infarct healing",
"     </li>",
"     <li>",
"      Electrophysiologic effects and electrical stability, including a reduction in the incidence and duration of sustained ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/15\">",
"       15",
"      </a>",
"      ], lower incidence of induced ventricular tachycardia, a reduced frequency of late potentials on a signal averaged ECG, and reduction in QT dispersion",
"     </li>",
"     <li>",
"      Perfusion of hibernating myocardium",
"     </li>",
"     <li>",
"      Collateral blood supply to distant ischemic myocardium (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=see_link\">",
"       \"Coronary collateral circulation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patent artery and degree of residual stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of coronary angiograms obtained in 2119 patients entered into the TIMI 4, 10A, 10B, and 14 trials found the following results at 90 minutes after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Only 9 percent of patients had a patent culprit artery and &lt;50 percent residual luminal diameter stenosis",
"     </li>",
"     <li>",
"      71 percent had a patent artery and &ge;50 percent residual stenosis,",
"     </li>",
"     <li>",
"      20 percent had a totally occluded vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to those with a patent artery and &ge;50 percent residual stenosis, those with mild residual stenosis were younger, had fewer prior infarctions, and fewer eccentric or ulcerated lesions, but also had a greater thrombus burden. A milder residual stenosis was associated with a lower incidence of in-hospital death, myocardial infarction, or heart failure (2.8 versus 7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predictors of early IRA patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to establish variables of greatest importance for determining early IRA patency, defined as TIMI grade 3 flow after fibrinolysis, the GUSTO 1 angiographic substudy analyzed data from 1030 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/17\">",
"     17",
"    </a>",
"    ]. Predictors of TIMI grade 3 flow at 90 minutes included&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of an accelerated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      regimen",
"     </li>",
"     <li>",
"      The IRA (right and circumflex versus left anterior descending)",
"     </li>",
"     <li>",
"      History of cigarette smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     ST segment resolution and IRA",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST segment resolution also correlates with IRA patency and TIMI flow grade (",
"    <a class=\"graphic graphic_figure graphicRef66373 \" href=\"UTD.htm?38/52/39758\">",
"     figure 2",
"    </a>",
"    ). This was seen in the TIMI 14 trial of 444 patients with interpretable ECGs who underwent angiography at 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/18\">",
"     18",
"    </a>",
"    ]. Seventy-nine percent of those with complete (&ge;70 percent) ST segment resolution had TIMI grade 3 flow and their 30-day mortality was 1 percent. In contrast, patients with partial or no ST segment resolution were less likely to have TIMI grade 3 flow (50 and 44 percent, respectively) and had a higher 30-day mortality (4.2 and 5.9 percent, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef73003 \" href=\"UTD.htm?9/59/10174\">",
"     figure 3",
"    </a>",
"    ). Although patients without ST segment resolution may still have a patent coronary artery, they are nevertheless at increased risk for mortality, which is likely due to extensive microvascular and tissue injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary artery patency versus perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite angiographic evidence of an open infarct-related coronary artery, patients may have slow coronary artery flow (&le;TIMI grade 2 flow) and a mismatch between patency and myocardial perfusion may be observed (no-reflow phenomenon), resulting in persistent left ventricular dysfunction; this may be due to irreversible myocardial necrosis, to reversible myocardial injury or stunning, to macro or microcirculatory perfusion abnormalities (microvascular dysfunction), or to a residual stenosis. Improvement after stenting is expected in patients with a residual stenosis but not in those with evidence of microvascular damage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/19\">",
"     19",
"    </a>",
"    ]. Optimal therapy of no-reflow is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood flow in nonculprit artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although reperfusion trials have focused on blood flow in the culprit artery, flow in the nonculprit arteries is also of importance. It has been assumed that flow in these arteries is normal, but data are limited. One report measured the corrected TIMI frame count (ie, the number of frames required for contrast to reach a standardized distal landmark) in 1817 nonculprit arteries of patients entered into the TIMI 4, 10A, 10B, and 14 fibrinolytic trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/20\">",
"     20",
"    </a>",
"    ]. At 90 minutes, blood flow in the nonculprit vessels was 45 percent slower than normal flow in the absence of a myocardial infarction. Patients with reduced blood flow in nonculprit arteries had a higher incidence of regional wall motion abnormalities within the distribution of the nonculprit vessel. Culprit and nonculprit blood flows were directly related at baseline, and relief of the residual stenosis in the culprit artery with angioplasty restored its flow to a level equal to the nonculprit artery; however, after angioplasty, blood flow in both culprit and nonculprit arteries remained 45 percent below normal.",
"   </p>",
"   <p>",
"    Correlates of slower nonculprit artery flow included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulsatile flow pattern (systolic flow reversal) in the nonculprit artery",
"     </li>",
"     <li>",
"      Left anterior descending culprit artery location",
"     </li>",
"     <li>",
"      Decreased systolic blood pressure",
"     </li>",
"     <li>",
"      Reduced cardiac output on ventriculography",
"     </li>",
"     <li>",
"      Decreased double product",
"     </li>",
"     <li>",
"      Greater percent of stenosis in the nonculprit artery",
"     </li>",
"     <li>",
"      Greater percent of the culprit artery bed lying distal to the stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microvascular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, successful reperfusion after an acute MI has generally been defined as restoration of normal flow in the infarct-related epicardial coronary artery. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'TIMI flow grade'",
"    </a>",
"    above.) However, even after restoration of patency in the IRA, there may be a persistent impairment in tissue perfusion due to microvascular dysfunction. This has been called the no-reflow phenomenon and has been a particular problem after primary PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microvascular dysfunction is also a component of ischemia-reperfusion injury. Brief periods of ischemia at the onset of reperfusion, a phenomenon called ischemic postconditioning, may improve microvascular flow and reduce infarct size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical implications of ischemic preconditioning\", section on 'Ischemic postconditioning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPONTANEOUS REPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous reperfusion occurs in both ST elevation and non-ST elevation MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although primary PCI or fibrinolysis is standard therapy for acute ST elevation MI, spontaneous reperfusion occurs in an increasing proportion of patients over time. It has been estimated that, in the absence of reperfusion therapy, the proportion of patients with an ST elevation MI who have an occluded IRA falls from 87 percent at four hours to 65 percent at 12 to 24 hours to 45 percent at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described below, the attainment of a patent IRA after fibrinolysis is associated with lower rates of morbidity and mortality. Outcomes are also improved with spontaneous reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the PAMI trials, for example, 16 percent of patients had TIMI 3 (normal) flow before PCI (ie, spontaneous reperfusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients with TIMI 3 flow had the following significant benefits: greater clinical and angiographic evidence of myocardial salvage; a lesser likelihood of presenting in or developing heart failure; and a lower rate of early and late mortality (six month mortality: 0.5 versus 2.8 and 4.4 percent with TIMI grade 2 and",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    flow, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous early reperfusion is much more common in patients with non-ST elevation acute coronary syndromes. Coronary arteriography, performed during the acute period in these disorders, demonstrates that the IRA is not occluded in 60 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The nonoccluding thrombi that are present are primarily grayish-white (ie, platelet-rich), and therefore less likely to respond to fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/28\">",
"     28",
"    </a>",
"    ], in contrast to being almost always reddish (ie, fibrin-rich) in patients with ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, microvascular perfusion is often reduced in patients with non-ST elevation acute coronary syndromes; as a result, the ongoing mechanism of ischemia is more likely embolization than epicardial vessel occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IRA PATENCY AND OUTCOME AFTER FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patency of the IRA after fibrinolytic therapy appears to have beneficial effects on both the short and long term outcome of patients with acute MI. This is most likely to occur when therapy is given within two to three hours of symptom onset (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 4",
"    </a>",
"    ). A meta-analysis from the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group found that the absolute mortality benefit from fibrinolytic therapy at five weeks was 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, spontaneous reperfusion before fibrinolytic therapy or PCI is also associated with a better prognosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Spontaneous reperfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Short-term morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting a beneficial effect of early IRA patency on mortality date back to the initial fibrinolytic trials. In the Western Washington Intracoronary Streptokinase trial, for example, patients with a patent IRA had a mortality at one month that was one-half that of patients with a closed artery. The difference in mortality between the two groups persisted at one year follow-up, as patients with patent IRAs had less than one-fifth the mortality of those with occluded arteries. Similar results were seen in the TIMI 1 trial, with impressive reductions in 21-day and one-year mortality in patients with patent IRAs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effect of coronary artery patency on short-term mortality suggested by early fibrinolytic trials was supported by an overview of four German multicenter clinical trials which included early coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/32\">",
"     32",
"    </a>",
"    ]. Complete reperfusion of the IRA as determined by coronary angiography 90 minutes after the initiation of fibrinolytic therapy was associated with the significant reduction in in-hospital mortality. In addition, only TIMI grade 3 flow conferred a survival benefit (2.7 percent); patients with TIMI grade 2 flow fared no better than those with TIMI",
"    <span class=\"nowrap\">",
"     0/I",
"    </span>",
"    flow (6.6 and 7.1 percent, respectively).",
"   </p>",
"   <p>",
"    This important observation has subsequently been confirmed by data from a number of other trials (",
"    <a class=\"graphic graphic_figure graphicRef82475 \" href=\"UTD.htm?38/12/39118\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. GUSTO 1, for example, tested the hypothesis that early and sustained patency of an infarct-related vessel is associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Forty-one thousand patients in over 1,000 hospitals in 15 countries with evolving myocardial infarction presenting within six hours of symptom onset were randomized to streptokinase (1.5 million units over 60 minutes) plus either subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (12,500 units BID) or intravenous heparin (5,000 unit bolus followed by 1,000 units per hour), or to accelerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) with intravenous heparin (accelerated refers to the rate at which alteplase is given). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .) A fourth arm consisted of a combination of streptokinase and alteplase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    was associated with a 1 percent absolute reduction in mortality (6.3 versus 7.3 percent) compared to streptokinase. The mortality benefit for alteplase was greatest in patients less than 75 years old and in those with anterior wall infarctions. The time of fibrinolysis was also important, independent of the fibrinolytic agent used (alteplase or streptokinase) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/37\">",
"     37",
"    </a>",
"    ]. Early fibrinolysis was associated with a lower 30 day mortality rate (less than two hours &mdash; 5.5 percent; greater than four hours &mdash; 9.0 percent).",
"   </p>",
"   <p>",
"    In the angiographic substudy, accelerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    produced TIMI 3 flow at 90 minutes in 54 percent compared to only 30 to 33 percent for the streptokinase groups. Patency rates for streptokinase and alteplase were only different at the 90 minute mark. Over time, streptokinase \"caught up\" with alteplase so that patency for both agents was similar at four hours. The earlier and more complete infarct vessel patency associated with alteplase at 90 minutes appears to contribute to the lower mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When data from 11,228 patients enrolled in GUSTO 1 were analyzed, 45 percent of patients overall had an open IRA, defined as the presence of TIMI grade 3 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/38\">",
"     38",
"    </a>",
"    ]. Those with an open artery had a lower 30 day mortality (1.5 versus 6.3 percent for a closed artery) even after adjusting for baseline clinical predictors of outcome including ejection fraction. At one year, the mortality rate among those surviving after the first 30 days was still lower for those with an open vessel (3.3 versus 8.8 percent); however, after adjusting for clinical variables, patency was no longer a significant predictor and the only predictor of mortality was the left ventricular ejection fraction (LVEF) (",
"    <a class=\"graphic graphic_figure graphicRef56352 \" href=\"UTD.htm?32/32/33293\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patency also is associated with lower morbidity. This was illustrated in a study of 327 patients who received fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/39\">",
"     39",
"    </a>",
"    ]. Those with coronary artery reperfusion based upon clinical markers (eg, relief of pain, &ge;50 percent reduction in the sum of ST segment elevation, and abrupt initial release of creatine kinase levels &gt;2 fold over normal) not only had a lower 30-day mortality (3.8 versus 16.2 percent for those without evidence of reperfusion), but also had a lower incidence of heart failure (10.5 versus 23.1 percent) and less often progressed to cardiogenic shock (0.5 versus 12.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Long-term mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved long-term prognosis attributable to patency of the infarct-related artery is supported by several studies which analyzed different types of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/40-47\">",
"     40-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Single-vessel coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study retrospectively analyzed patients with single-vessel coronary artery disease who underwent cardiac catheterization following myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/41\">",
"     41",
"    </a>",
"    ]. These patients had not received a fibrinolytic agent. Patients with partial or complete anterograde flow were compared to those with minimal or no flow through the infarct-related artery. Survival correlated most significantly with a patent IRA. Over a five-year follow-up period,",
"    <strong>",
"     no",
"    </strong>",
"    patients with a patent IRA died compared to an 18 percent mortality observed in those with minimal IRA perfusion (p&lt;0.001). Heart failure, unstable angina, and recurrent MI were also more common in patients with minimal perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     TIMI flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GUSTO 1 trial evaluated the importance of TIMI flow grade in 2431 patients with a myocardial infarction who received fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/47\">",
"     47",
"    </a>",
"    ]. The two-year mortality for those with TIMI 3 flow was 7.9 percent compared to 15.7 percent for those with lesser flow grades (hazard ratio 0.48) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/47\">",
"     47",
"    </a>",
"    ]. When survival after 30 days was analyzed separately, there was an additional 3.3 percent mortality in those with TIMI 3 flow compared with 8.3 percent for lesser flow grades (hazard ratio 0.39); thus, the benefit of having TIMI 3 flow continued after the acute phase (a gain of 5 lives per 100 during this period). This benefit was independent of left ventricular ejection fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anterior MI and LAD perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ISAM (Intravenous Streptokinase Acute Myocardial infarction) trial, 368 patients in whom reperfusion was achieved were subsequently followed for approximately three years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/43\">",
"     43",
"    </a>",
"    ]. Angiographic evaluation was generally performed one month following MI. Using a strict definition of patency that incorporated both TIMI flow grade and stenosis severity of the IRA, mortality in patients with an anterior MI who had a patent LAD was 8 percent compared with 28 percent in those with an occluded artery (p&lt;0.03).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential importance of IRA patency in patients with left ventricular (LV) dysfunction was illustrated in a study of over 300 patients treated with fibrinolytic therapy who had coronary angiography performed one month following MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/45\">",
"     45",
"    </a>",
"    ]. Employing an occlusion score that considered both TIMI flow grade and the amount of myocardium supplied by the IRA, the investigators confirmed that patients with a LV ejection fraction (LVEF) less than 50 percent who had an occluded IRA (defined as less than TIMI 3 grade flow) experienced an adverse prognosis regardless of the myocardial distribution. In those with LVEF &gt;50 percent, an occluded vessel was associated with a poor prognosis when it supplied approximately 25 percent of the LV. The study clearly highlights the independent long-term prognostic importance of arterial patency in addition to LV function following fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     TIMI frame count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clear correlation between coronary flow and patient survival has stimulated enthusiasm for the development of more quantitative and precise measures than the semi-quantitative TIMI flow scale. It is hoped that increasingly accurate measures of coronary arterial flow velocity will minimize the limitation resulting from interobserver variability seen with the present system. The TIMI frame count, which is the number of cine frames required for dye to first reach standardized distal coronary landmarks, has shown great promise, particularly in defining low-risk and high-risk patient subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study measured the TIMI frame count in 1248 patients treated with fibrinolytic agents in the TIMI 4, 10, and 10B trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/49\">",
"     49",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who died in the hospital had a higher frame count (slower flow) compared to survivors (70 versus 50); a higher frame count was also observed in those who died by 30 to 42 days. In a multivariate model that excluded the TIMI flow grade, there was a 0.7 percent increase in absolute mortality for every 10-frame rise.",
"     </li>",
"     <li>",
"      The frame count further stratified patients with TIMI grade 3 flow. Although a frame count &le;40 is associated with TIMI grade 3 flow, those with a frame count &le;20 had a 7.9 percent incidence of in-hospital adverse events (death, recurrent infarction, shock, congestive heart failure or left ventricular ejection fraction &le;40 percent) compared to 15.5 percent for those with a frame count between 21 and 40.",
"     </li>",
"     <li>",
"      Patients who had an adverse in-hospital outcome (death, recurrent infarction, shock, heart failure, or ejection fraction &le;40 percent) had a slower global TIMI frame count (ie, the average of all three coronary arteries) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another small study of 104 patients with a first MI found that a lower TIMI frame count (faster flow) immediately after successful PCI (TIMI flow grade 3) predicted recovery of regional LV function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although intraobserver and interobserver reproducibility of the TIMI frame count is good, there are factors that can introduce variability and decrease the TIMI frame count, including nitrate use, increasing heart rate, and injection of dye during the beginning of diastole (versus the beginning of systole) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Assessing myocardial perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of myocardial perfusion is highly relevant because tissue level blood flow is a major determinant of ventricular salvage and viability following acute MI. The TIMI myocardial perfusion grade (TMPG) is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade O - Indicates the failure of contrast dye to enter the microvasculature",
"     </li>",
"     <li>",
"      Grade 1 - The dye slowly enters the microvasculature but fails to exit",
"     </li>",
"     <li>",
"      Grade 2 &ndash; The dye entry to and exit from the microvasculature is delayed (in comparison to the noninfarct-related areas)",
"     </li>",
"     <li>",
"      Grade 3 - The dye enters and exits the microvasculature normally. A relationship between myocardial perfusion and clinical outcome has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further work in this area is needed, particularly if angiographic flow grade is to be used as a surrogate end point in the development of new fibrinolytics and adjunctive treatment strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Plaque morphology and coronary blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between plaque rupture and coronary thrombosis among patients with acute coronary syndromes is well established. Rupture involving the proximal aspect of an atheromatous plaque, compared to mid-or distal plaque rupture is much more likely to cause occlusive thrombus, TIMI O blood flow and ST-segment elevation MI. A larger proportion of fibro-fatty material, as determined by intravascular ultrasound and greater overall plaque burden associated with reduced myocardial blood flow (myocardial blush grade) and no reflow in patients with MI and TIMI 3 coronary artery blood flow following primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Coronary no reflow, thrombus characteristics and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of successful myocardial perfusion despite infarct-related vessel patency (no reflow phenomenon) is associated with large infarction size, reduced left ventricular performance, clinical congestive heart failure and increased mortality. In addition to platelet, leukocyte and atheromatous debris, as well as endothelial cell swelling, patients with no reflow exhibit a more compact fibrin network and resistance to fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     IRA PATENCY AND OUTCOME AFTER PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues related to IRA patency and PCI: reocclusion after PCI; and late PCI to open an occluded artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Reocclusion after PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late reocclusion after successful PCI has a negative impact on long-term survival. This was illustrated in a review of 528 patients with a patent IRA after a successful PCI who underwent a repeat angiogram at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/57\">",
"     57",
"    </a>",
"    ]. At 5.7 year follow-up, those with reocclusion had a higher actuarial eight year total mortality rate (28 versus 10 percent) and higher cardiovascular mortality (25 versus 7 percent) compared to those without reocclusion; the impact on long-term survival was greater in those with an anterior wall MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LATE PCI TO OPEN AN OCCLUDED ARTERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will address the difficult issue of when to consider percutaneous coronary intervention (PCI) later than 24 hours after STEMI. The discussion of when to consider PCI between 12 and 24 hours after STEMI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H16#H16\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Presentation after 12 hours'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinolytic therapy administered more than 24 hours after the onset of acute ST elevation MI does not improve clinical outcome (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 4",
"    </a>",
"    ), possibly because it does not restore artery patency. Although early PCI is also optimal, some have suggested that late PCI to open an occluded artery might be of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recovery of left ventricular function decreases with later PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/58\">",
"     58",
"    </a>",
"    ], but late PCI may still be beneficial at a time when fibrinolytic therapy is no longer effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/59\">",
"     59",
"    </a>",
"    ]. This is an important issue, since registry data suggest that 9 to 31 percent of patients with an STEMI present more than 12 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It has been estimated that, in the absence of reperfusion, an occluded IRA is present in 87 percent of patients with an STEMI at four hours, 65 percent at 12 to 24 hours, and 45 percent at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible mechanism for benefit from late PCI is residual antegrade or collateral blood flow, which was present in 73 percent of patients in the BRAVE-2 trial cited below [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/62\">",
"     62",
"    </a>",
"    ]. The low rate of persistent flow may maintain myocardial viability and therefore infarct size until blood flow is restored by PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Mechanisms other than myocardial salvage, such as prevention of ventricular remodeling, also may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two settings in which late PCI might be performed: in previously untreated patients, which will be reviewed here; and in patients previously treated with fibrinolytic therapy, which is a form of adjunctive or early elective PCI that will be discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H15#H15\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Adjunctive or early elective PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential benefit of late PCI was suggested by observational data from the National Registry of Myocardial Infarction (NRMI)-2 of 7358 patients with acute STEMI who presented more than 12 hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients undergoing PCI (22 percent of the group) had a significantly lower incidence of recurrent ischemia or angina, recurrent MI, and in-hospital mortality (3.4 versus 6.6 percent without PCI); the association between PCI and lower mortality persisted after adjusting for factors associated with a higher in-hospital mortality (odds ratio 0.67, 95% CI 0.49-0.92). With a propensity analysis, which helps to adjust for treatment selection bias, there was still a significant reduction in recurrent ischemia with PCI (10.8 versus 14.6 percent), and a strong trend toward a reduction in in-hospital mortality (odds ratio 0.73, 95% CI 0.53-1.01).",
"   </p>",
"   <p>",
"    The randomized trials &mdash; BRAVE-2, DECOPI, and OAT &mdash; that have evaluated late PCI have included patients at different time periods after symptom onset, ranging from more than 12 hours to up to 28 days. Some have demonstrated an improvement in left ventricular function with intervention, but none has demonstrated a significant benefit on hard clinical outcomes.",
"   </p>",
"   <p>",
"    The SWISSI II trial, which randomly assigned patients with both STEMI (including many treated with fibrinolytic therapy) and NSTEMI to late PCI or medical therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link&amp;anchor=H15#H15\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Treatment with revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BRAVE-2 trial evaluated 365 patients who presented with an acute STEMI 12 to 48 hours (median 23 hours) after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/62\">",
"     62",
"    </a>",
"    ]. The patients, who were no longer symptomatic, were randomly assigned to an invasive strategy, which primarily consisted of PCI with stenting, or conventional conservative therapy. The primary end point was infarct size at 5 to 10 days as determined by Tc-99m sestamibi SPECT imaging. There were two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Final left ventricular infarct size was significantly smaller in the late PCI group (median 8 versus 13 percent). The size of the infarct with conservative therapy was smaller than the expected value of 20 percent and may have reflected some antegrade flow and some collateral flow to the infarct zone.",
"     </li>",
"     <li>",
"      The secondary end point of death, recurrent MI, or stroke occurred less often with late PCI (4.4 versus 6.6 percent). Although this difference was not significant (relative risk 0.67, 95% CI 0.27-1.62), the study was underpowered to detect such a modest difference in clinical outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of primary PCI performed even later was evaluated in the DECOPI and OAT trials. Neither showed a mortality benefit from intervention. In DECOPI, 212 patients with a first STEMI and an occluded infarct-related artery who were seen 2 to 15 days (mean 5 days after symptom onset) underwent coronary angiography and were randomly assigned to continued medical therapy or PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/68\">",
"     68",
"    </a>",
"    ]. Most patients had single vessel disease and only 13 percent had been treated with fibrinolytic therapy.",
"   </p>",
"   <p>",
"    At six months, more patients in the intervention group had a patent infarct-related artery (82 versus 34 percent) and the LVEF was 5 percent higher (59 versus 54 percent), a benefit seen only in those with patent infarct-related arteries. However, at a mean follow-up of 34 months, the primary end point (a composite of cardiac death, nonfatal MI, or ventricular tachyarrhythmia) was not significantly different in the two groups (7.3 versus 8.7 percent).",
"   </p>",
"   <p>",
"    The much larger Occluded Artery Trial (OAT) included 2166 stable patients who had an occluded IRA as determined by cardiac catheterization performed 3 to 28 days after acute STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/69\">",
"     69",
"    </a>",
"    ]. The patients were randomly assigned to optimal medical therapy alone or with routine PCI with stenting. Important characteristics of the patients in this trial included high-risk features (left ventricular ejection fraction [LVEF] less than 50 percent or proximal occlusion of a major epicardial vessel) and the absence of recurrent clinical ischemia or the demonstration of severe ischemia on stress testing. Twenty percent had received fibrinolytic therapy.",
"   </p>",
"   <p>",
"    The primary end point was a composite of death, myocardial reinfarction, or New York Heart Association class IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). At four years, the rate of the composite end point was not statistically different between the PCI and the medical therapy groups (17.2 and 15.6 percent, respectively). It should be emphasized that this neutral result was obtained despite the presence of retained viability in about 600 of patients. At six-year median survivor follow-up, there was no significant difference between the two treatment strategies in the rates of either the primary end point or its components [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The logic for attempts to demonstrate the value of late opening of an occluded IRA in the OAT trial was based upon the presumption that treated patients would have an improvement in LVEF compared to patients who did not undergo PCI. TOSCA-2, an angiographic follow-up substudy of 381 patients in OAT, was not able to demonstrate a greater improvement in LVEF in patients with PCI than in those receiving medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/71\">",
"     71",
"    </a>",
"    ]. At one year, there was no significant difference between the PCI and medical therapy groups with regard to the increases seen in LVEF (48.3 to 52.5 and 48.0 to 51.2 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above trials demonstrated an improvement in left ventricular function with PCI, but not a significant benefit on hard clinical outcomes such as mortality. An attempt to further evaluate this discrepancy was made in a meta-analysis of ten trials (including OAT, DECOPI, BRAVE II and SWISSI II) in which 3,560 stable patients were randomly assigned to either late (12 hours to 26 days) PCI or medical therapy after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/72\">",
"     72",
"    </a>",
"    ]. At an average follow-up of 2.8 years patients who underwent late PCI had a significantly better long-term survival than those who received medical therapy (6.3 versus 8.4 percent, odds ratio for death 0.49, 95% CI 0.26 to 0. 94). However, the results of this meta-analysis need to be interpreted with extreme caution as the trials included were very heterogeneous. Indeed, 16 percent of the patients had an open artery at the time of angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2418744\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence that can be applied to answer the question of whether late PCI (after 24 hours) of the infarct related artery in stable patients improves outcomes does not allow for a firm conclusion. We agree with recommendations made in the 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association focused update of prior STEMI guidelines (not changed in the 2009 focused update) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A weak recommendation for PCI of a hemodynamically significant stenosis in a patent infarct artery",
"      <br/>",
"     </li>",
"     <li>",
"      A strong recommendation against PCI of a totally occluded infarct artery in asymptomatic, stable patients who have no evidence of severe ischemia and have one or two vessel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2008 European Society guidelines on the Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation does not address this issue and states that there is limited experience with PCI in STEMI patients presenting more than 12 hours after onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/50/5930/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to similar patients who present between 12 and 24 hours is also not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LONG-TERM VALUE OF A PATENT IRA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the best data on the long-term prognostic importance of IRA patency comes from the SAVE trial. In the SAVE trial of post-MI patients with LV dysfunction, an occluded IRA was an independent predictor of all-cause mortality (24 versus 14 percent for patients with an occluded or patent IRA, respectively), cardiovascular mortality (23 versus 12 percent), and the composite end point of cardiovascular mortality or morbidity (51 versus 37 percent) at an average follow-up of 3.5 years.",
"   </p>",
"   <p>",
"    The salutary effects of IRA patency in SAVE were independent of the benefits associated with medical therapy (which included angiotensin-converting enzyme inhibition and beta blockade). This study differed from other studies in that IRA patency was a prespecified ancillary end point; the analysis was restricted to post-MI patients with LV dysfunction without clinically apparent ischemia or heart failure, baseline coronary anatomy was known in all patients, a variety of treatment strategies culminating in IRA patency were included, and corrections for clinical variables, including LV function, were made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258089163\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with an acute ST elevation myocardial infarction (STEMI), over 90 percent have complete occlusion of the culprit artery. Patency can be achieved by fibrinolysis or primary percutaneous coronary intervention (PCI). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early and sustained coronary arterial patency limits infarct size, which is a major determinant of long-term left ventricular performance. Patency of the infarct related artery after reperfusion with either fibrinolytic therapy or PCI has beneficial effects (including survival) on both the short- and long-term outcome of patients with acute MI. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'IRA patency and outcome after fibrinolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Reocclusion after PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies comparing medical therapy and PCI with the intent to restore patency of an occluded coronary artery beyond 24 hours from MI onset have generally not demonstrated better outcomes with the latter. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Late PCI to open an occluded artery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/1\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/2\">",
"      Reiner JS, Lundergan CF, van den Brand M, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1994; 24:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/3\">",
"      SALISBURY PF, CROSS CE, RIEBEN PA. Influence of coronary artery pressure upon myocardial elasticity. Circ Res 1960; 8:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/4\">",
"      Connelly CM, Ngoy S, Schoen FJ, Apstein CS. Biomechanical properties of reperfused transmural myocardial infarcts in rabbits during the first week after infarction. Implications for left ventricular rupture. Circ Res 1992; 71:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/5\">",
"      Ono S, Waldman LK, Yamashita H, et al. Effect of coronary artery reperfusion on transmural myocardial remodeling in dogs. Circulation 1995; 91:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/6\">",
"      Kersschot IE, Brugada P, Ramentol M, et al. Effects of early reperfusion in acute myocardial infarction on arrhythmias induced by programmed stimulation: a prospective, randomized study. J Am Coll Cardiol 1986; 7:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/7\">",
"      Th&eacute;roux P, Morissette D, Juneau M, et al. Influence of fibrinolysis and percutaneous transluminal coronary angioplasty on the frequency of ventricular premature complexes. Am J Cardiol 1989; 63:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/8\">",
"      Sager PT, Perlmutter RA, Rosenfeld LE, et al. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/9\">",
"      Hii JT, Traboulsi M, Mitchell LB, et al. Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant ventricular tachyarrhythmias. Circulation 1993; 87:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/10\">",
"      Gang ES, Lew AS, Hong M, et al. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/11\">",
"      Aguirre FV, Kern MJ, Hsia J, et al. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction. Am J Cardiol 1991; 68:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/12\">",
"      Endoh Y, Kasanuki H, Ohnishi S, et al. Influence of early coronary reperfusion on QT interval dispersion after acute myocardial infarction. Pacing Clin Electrophysiol 1997; 20:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/13\">",
"      Levy WC, Cerqueira MD, Weaver WD, Stratton JR. Early patency of the infarct-related artery after myocardial infarction preserves diastolic filling. Am J Cardiol 2001; 87:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/14\">",
"      Sheiban I, Fragasso G, Rosano GM, et al. Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2001; 38:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/15\">",
"      Opitz CF, Finn PV, Pfeffer MA, et al. Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage. J Am Coll Cardiol 1998; 32:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/16\">",
"      Llevadot J, Giugliano RP, McCabe CH, et al. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol 2000; 85:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/17\">",
"      Lundergan CF, Reiner JS, McCarthy WF, et al. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 32:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/18\">",
"      de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol 2000; 85:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/19\">",
"      Akasaka T, Yoshida K, Kawamoto T, et al. Relation of phasic coronary flow velocity characteristics with TIMI perfusion grade and myocardial recovery after primary percutaneous transluminal coronary angioplasty and rescue stenting. Circulation 2000; 101:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/20\">",
"      Gibson CM, Ryan KA, Murphy SA, et al. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 34:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/21\">",
"      Betriu A, Casta&ntilde;er A, Sanz GA, et al. Angiographic findings 1 month after myocardial infarction: a prospective study of 259 survivors. Circulation 1982; 65:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/22\">",
"      Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/23\">",
"      De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/24\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/25\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/26\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/27\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/28\">",
"      Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/29\">",
"      Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/30\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/31\">",
"      Kennedy JW, Ritchie JL, Davis KB, et al. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 1985; 312:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/32\">",
"      Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/33\">",
"      Becker RC. Late thrombolytic therapy: mechanism of benefit and potential risk among patients treated beyond 6 hours. Coron Artery Dis 1993; 4:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/34\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/35\">",
"      Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995; 25:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/36\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/37\">",
"      Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/38\">",
"      Puma JA, Sketch MH Jr, Thompson TD, et al. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol 1999; 83:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/39\">",
"      Pom&eacute;s Iparraguirre H, Conti C, Grancelli H, et al. Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. Am Heart J 1997; 134:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/40\">",
"      Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/41\">",
"      Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 1989; 64:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/42\">",
"      McCully RB, elZeky F, vanderZwaag R, et al. Impact of patency of the left anterior descending coronary artery on long-term survival. Am J Cardiol 1995; 76:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/43\">",
"      Schr&ouml;der R, Neuhaus KL, Linderer T, et al. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). Am J Cardiol 1989; 64:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/44\">",
"      Galvani M, Ottani F, Ferrini D, et al. Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. Am J Cardiol 1993; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/45\">",
"      White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/46\">",
"      Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation 1995; 92:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/47\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/48\">",
"      French JK, Ellis CJ, Webber BJ, et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. Am J Cardiol 1998; 81:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/49\">",
"      Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999; 99:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/50\">",
"      Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol 2001; 38:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/51\">",
"      Abaci A, Oguzhan A, Eryol NK, Ergin A. Effect of potential confounding factors on the thrombolysis in myocardial infarction (TIMI) trial frame count and its reproducibility. Circulation 1999; 100:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/52\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/53\">",
"      Seyfeli E, Abaci A, Kula M, et al. Myocardial blush grade: to evaluate myocardial viability in patients with acute myocardial infarction. Angiology 2007; 58:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/54\">",
"      Nakamura T, Kubo N, Ako J, Momomura S. Angiographic no-reflow phenomenon and plaque characteristics by virtual histology intravascular ultrasound in patients with acute myocardial infarction. J Interv Cardiol 2007; 20:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/55\">",
"      Tanaka A, Shimada K, Namba M, et al. Relationship between longitudinal morphology of ruptured plaques and TIMI flow grade in acute coronary syndrome: a three-dimensional intravascular ultrasound imaging study. Eur Heart J 2008; 29:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/56\">",
"      Zalewski J, Undas A, Godlewski J, et al. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol 2007; 27:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/57\">",
"      Bauters C, Delomez M, Van Belle E, et al. Angiographically documented late reocclusion after successful coronary angioplasty of an infarct-related lesion is a powerful predictor of long-term mortality. Circulation 1999; 99:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/58\">",
"      Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/59\">",
"      Sch&ouml;mig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 2003; 108:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/60\">",
"      Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/61\">",
"      Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/62\">",
"      Sch&ouml;mig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005; 293:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/63\">",
"      Gibbons RJ, Grines CL. Acute PCI for ST-segment elevation myocardial infarction: is later better than never? JAMA 2005; 293:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/64\">",
"      Clements IP, Christian TF, Higano ST, et al. Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation 1993; 88:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/65\">",
"      Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 1993; 88:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/66\">",
"      Pizzetti G, Belotti G, Margonato A, et al. Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1996; 28:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/67\">",
"      Elad Y, French WJ, Shavelle DM, et al. Primary angioplasty and selection bias inpatients presenting late (&gt;12 h) after onset of chest pain and ST elevation myocardial infarction. J Am Coll Cardiol 2002; 39:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/68\">",
"      Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J 2004; 25:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/69\">",
"      Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/70\">",
"      Hochman JS, Reynolds HR, Dzav&iacute;k V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation 2011; 124:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/71\">",
"      Dzav&iacute;k V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 2006; 114:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/72\">",
"      Abbate A, Biondi-Zoccai GG, Appleton DL, et al. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/73\">",
"      Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/50/5930/abstract/74\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 49 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5930=[""].join("\n");
var outline_f5_50_5930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H258089163\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMI FLOW GRADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPEN VESSEL HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patent artery and degree of residual stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predictors of early IRA patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - ST segment resolution and IRA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary artery patency versus perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood flow in nonculprit artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microvascular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPONTANEOUS REPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IRA PATENCY AND OUTCOME AFTER FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Short-term morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Long-term mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Single-vessel coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anterior MI and LAD perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TIMI frame count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Assessing myocardial perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Plaque morphology and coronary blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Coronary no reflow, thrombus characteristics and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      IRA PATENCY AND OUTCOME AFTER PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Reocclusion after PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LATE PCI TO OPEN AN OCCLUDED ARTERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2418744\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LONG-TERM VALUE OF A PATENT IRA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258089163\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/49\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/49|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/59/36787\" title=\"figure 1\">",
"      Factors for TIMI grade flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/52/39758\" title=\"figure 2\">",
"      ST resolution vs TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/59/10174\" title=\"figure 3\">",
"      ST segment resolution and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 4\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/12/39118\" title=\"figure 5\">",
"      IRA patency and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33293\" title=\"figure 6\">",
"      LVEF predicts one-year mortality after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/49|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_50_5931="Normal growth rates children";
var content_f5_50_5931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal growth rates in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Height velocity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infancy (0 to 12 months)",
"       </td>",
"       <td>",
"        25 cm/y",
"       </td>",
"       <td>",
"        7 kg/y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toddler (12 to 24 months)",
"       </td>",
"       <td>",
"        11 cm/y",
"       </td>",
"       <td>",
"        2.5 kg/y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preschool/school age",
"       </td>",
"       <td>",
"        6 cm/y",
"       </td>",
"       <td>",
"        2.5 kg/y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adolescent",
"       </td>",
"       <td>",
"        3-4 cm/6 mo",
"       </td>",
"       <td>",
"        3 kg/6 mo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5931=[""].join("\n");
var outline_f5_50_5931=null;
var title_f5_50_5932="Brain abscess neuro deficits";
var content_f5_50_5932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic deficits in brain abscess by location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Temporal lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Werincke's aphasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homonymous superior quadranopsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild contralateral facial muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Frontal lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drowsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inattentive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disturbed judgment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of grasp, suck and snout reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contralateral hemiparesis (when the abscess is large)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parietal lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired position sense, two point discrimination and stereognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal sensory and motor seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homonymous hemianopsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired opticokinetic nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cerebellar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nystagmus (coarser on gaze toward the lesion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ipsilaterial incoordination of arm and leg movements with intention tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Brainstem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial weakness and dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple other cranial nerve palsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contralateral hemiparesis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5932=[""].join("\n");
var outline_f5_50_5932=null;
var title_f5_50_5933="Alliance-relevant aspects of personality disorder styles";
var content_f5_50_5933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F83283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F83283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aspects of personality disorder styles relevant to the therapeutic relationship",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Personality disorder/traits",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alliance challenges",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points of possible engagement in treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizotypal",
"       </td>",
"       <td>",
"        <p>",
"         Suspiciousness/paranoia",
"        </p>",
"        <p>",
"         Profound interpersonal discomfort",
"        </p>",
"        Bizarre thinking",
"       </td>",
"       <td>",
"        Possible motivation for human connection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizoid",
"       </td>",
"       <td>",
"        <p>",
"         Social detachment",
"        </p>",
"        Emotional aloofness",
"       </td>",
"       <td>",
"        Underlying neediness and sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paranoid",
"       </td>",
"       <td>",
"        <p>",
"         Expectations of harm or exploitation",
"        </p>",
"        <p>",
"         Hypersensitivity to perceived criticism",
"        </p>",
"        Inclination to withdraw or attack",
"       </td>",
"       <td>",
"        Underlying need for affirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borderline",
"       </td>",
"       <td>",
"        <p>",
"         Unstable emotional and cognitive states",
"        </p>",
"        <p>",
"         Extremely demanding",
"        </p>",
"        Proneness to acting-out",
"       </td>",
"       <td>",
"        <p>",
"         Relationship-seeking",
"        </p>",
"        Responds to warmth and support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcissistic",
"       </td>",
"       <td>",
"        <p>",
"         Need for constant positive regard",
"        </p>",
"        <p>",
"         Contempt for others",
"        </p>",
"        Grandiose sense of entitlement",
"       </td>",
"       <td>",
"        Responds over time to empathy and affirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histrionic",
"       </td>",
"       <td>",
"        <p>",
"         Attempts to charm and entertain",
"        </p>",
"        <p>",
"         Emotionally labile",
"        </p>",
"        Unfocused cognitive style",
"       </td>",
"       <td>",
"        <p>",
"         Relationship-seeking",
"        </p>",
"        Responds to warmth and support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antisocial",
"       </td>",
"       <td>",
"        <p>",
"         Controlling",
"        </p>",
"        <p>",
"         Tendency to lie and manipulate",
"        </p>",
"        <p>",
"         No empathy or regard for others",
"        </p>",
"        Use of pseudoalliance to gain some advantage",
"       </td>",
"       <td>",
"        May engage in treatment if in self-interest or if Axis I symptoms cause sufficient distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoidant",
"       </td>",
"       <td>",
"        <p>",
"         Expectations of criticism or rejection",
"        </p>",
"        <p>",
"         Proneness to shame and humiliation",
"        </p>",
"        Reluctance to disclose information",
"       </td>",
"       <td>",
"        <p>",
"         Responds to warmth/empathy",
"        </p>",
"        Desire for relationships in spite of vulnerabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dependent",
"       </td>",
"       <td>",
"        <p>",
"         No value placed on independence/taking initiative",
"        </p>",
"        Submission leading to pseudoalliance",
"       </td>",
"       <td>",
"        <p>",
"         Friendly and compliant",
"        </p>",
"        Likely to stay in treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obsessive-compulsive",
"       </td>",
"       <td>",
"        <p>",
"         Need for control",
"        </p>",
"        <p>",
"         Perfectionistic toward self and others",
"        </p>",
"        <p>",
"         Fear of criticism from therapist",
"        </p>",
"        <p>",
"         Restricted affect",
"        </p>",
"        Stubbornness",
"       </td>",
"       <td>",
"        <p>",
"         Conscientious",
"        </p>",
"        <p>",
"         Use of intellectualization may be helpful at times",
"        </p>",
"        Will try to be a \"good patient\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American Psychiatric Textbook of Personality Disorders, (Copyright &copy; 2005). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5933=[""].join("\n");
var outline_f5_50_5933=null;
var title_f5_50_5934="Pulse pressure risk CHD";
var content_f5_50_5934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Pulse pressure is an independent risk factor for coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Framingham study of 1924 men and women followed for 20 years a higher pulse pressure (PP) at any level of systolic blood pressure (SBP) was an indepedent risk factor for coronary heart disease (CHD). Hazard ratios were determined from level of PP within SBP groups; hazard ratios were set to a reference value of 1.0 for SBP of 130 mmHg and PP of 50 mmHg. All estimates were adjusted for age, sex, body mass index, cigarettes smoked per day, glucose intolerance, and total cholesterol/HDL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Franklin, SS, Khan, SA, Wong, ND, et al, Circulation 1999; 100:354.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5934=[""].join("\n");
var outline_f5_50_5934=null;
var title_f5_50_5935="TR isoform tissue distribution";
var content_f5_50_5935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Distribution of thyroid hormone receptors in different tissues of fetal and adult rats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 617px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Total triiodothyronin (T3) binding capacity in nuclei of different tissues.",
"    <br>",
"     (B) Distribution of different isoforms of TRs as determined by measurements using isoform-specfic antibodies.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: Schwartz HL, Lazar MA, Oppenheimer JH.&nbsp;Widespread distribution of immunoreactive thyroid hormone beta 2 receptor (TR beta 2) in the nuclei of extrapituitary rat tissues. J Biol Chem 1994; 269:24777.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_50_5935=[""].join("\n");
var outline_f5_50_5935=null;
